

Matthew T. Roe, M.D., M.H.S., F.A.C.C., F.E.S.C.

Duke University Medical Center
Duke Clinical Research Institute
2400 Pratt Street – Room 7034
Durham, NC 27705
Office Phone: 919-668-8959
Office Fax: 919-668-8665
Cell Phone: 919-971-1594
Email: matthew.roe@duke.edu
Twitter: @MTRHeart

Personal Information

Date of Birth: February 27, 1967
Place of Birth: Evanston, IL
Citizenship: U.S.A.

Appointments

Professor of Medicine
Division of Cardiology, Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC
January, 2016 – present

Associate Professor of Medicine, with Tenure
Division of Cardiology, Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC
January, 2011 – December, 2015

Associate Professor of Medicine
Division of Cardiology, Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC
October, 2007 – December, 2010

Assistant Professor of Medicine
Division of Cardiology, Department of Medicine

Duke University Medical Center
Duke Clinical Research Institute
Durham, NC
March, 2001 – September, 2007

Associate in Medicine
Division of Cardiology, Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC
July, 1999 – March, 2001

Education

Post-Graduate

Fellowship – Cardiology
Cleveland Clinic Foundation
Cleveland, OH
July, 1996 – June, 1999

Residency – Internal Medicine
Duke University Medical Center
Durham, NC
July, 1994 – June, 1996

Internship – Internal Medicine
Duke University Medical Center
Durham, NC
July, 1993 – June, 1994

Medical School

Doctor of Medicine
Duke University School of Medicine
Durham, NC
August, 1989 - May, 1993

Graduate

Master of Health Sciences in Clinical Research
Duke University School of Medicine
Durham, NC
August, 1999 – December, 2001

Undergraduate

Bachelor of Arts with Distinction
University of Virginia
Charlottesville, VA
Major: Interdisciplinary Studies
August, 1985 - May, 1989

Scholarly Societies

Phi Beta Kappa
Echol's Scholar

University of Virginia, 1989
University of Virginia, 1985

Certification

1996	Board Certified in Internal Medicine
1999	Board Certified in Cardiovascular Medicine
2009	Board Recertification in Cardiovascular Medicine

Licensure

1995-Present	Licensed in the State of North Carolina (95-00205)
1996-1999	Licensed in the State of Ohio (70530)

Clinical Practice

1999 – present	Clinical practice in cardiovascular medicine including: - Attending physician in the Coronary Intensive Care Unit - Attending physician on the inpatient general cardiology service - Outpatient clinic focusing upon general cardiovascular conditions including chronic coronary artery disease, atrial fibrillation, lipid disorders, hypertension, heart failure, and valvular heart disease
----------------	--

Memberships and Positions in Professional and Scientific Societies

American Heart Association (AHA)

1. AHA Clinical Cardiology Council – Since 2000
2. AHA Scientific Sessions Abstract Grader – Since 2005
3. AHA Writing Group Member - Development of Systems of Care for ST-Segment Elevation Myocardial Infarction (STEMI) Patients – 2006
4. AHA/ACC Guidelines Peer Reviewer - Focused Updates of the ACC/AHA 2004 Guidelines on the Management of Patients with ST-Elevation Myocardial Infarction – 2007
5. AHA Pharmaceutical Roundtable Outcomes Research Center – Awarded to Duke Clinical Research Institute
- Fellowship Director – 2008-2013
6. AHA Mission Lifeline Data Analytic Coordinating Center - Awarded to Duke Clinical Research Institute
- Co-Principal Investigator – 2010-Present
7. AHA Mission Lifeline Science Task Force Member – 2010-Present
8. AHA Scientific Program Sessions Builder: Program Planner – 2013-2015

American College of Cardiology (ACC)

1. Fellow of the American College of Cardiology – Since 2000
2. ACC Scientific Sessions Abstract Grader – Since 2004
3. National Cardiovascular Data Registry - Acute Coronary Treatment and Intervention Outcomes Network – Get With the Guidelines Registry (ACTION Registry-GWTG)
 - Ex-Oficio Steering Committee member: 2006-2010
 - Chairman of Research and Publications Sub-Committee: 2007-2010
 - Data Analytic Coordinating Center – Duke Clinical Research Institute
 - Principal Investigator – 2007-Present
4. National Cardiovascular Data Registry – Cath/PCI Registry
 - Data Analytic Coordinating Center – Duke Clinical Research Institute
 - Principal Investigator – 2006-Present
 - Ex-Oficio Member of Research and Publications Sub-Committee: 2009-Present
5. ACS Clinical Data Standards Work Group: August, 2007 – February, 2008

6. IC3 Registry Program Dataset Work Group: July, 2007 – October, 2007
7. National Cardiovascular Data Registry – Scientific Oversight Committee: 2010-Present
8. National Cardiovascular Data Registry – National Cardiovascular Research Infrastructure Data Standards Workgroup Committee Member: 2010-2011
9. National Cardiovascular Data Registry – Public Reporting Measurement Workgroup: 2010-2011
10. ACC/AHA NSTEMI Performance Measures Peer Reviewer – December, 2016

European Society of Cardiology (ESC)

1. Fellow of the European Society of Cardiology – Since 2012
2. ESC Scientific Sessions Abstract Grader – Since 2013

Manuscripts in Refereed Journals

1. Fleming TR, DeMets DL, **Roe MT**, Wittes J, Calis KA, Vora AN, Meisel A, Braun RP, Konstam MA, Pencina MJ, Gordon DJ, Mahaffey KW, Hennekens CH, Neaton JD, Pearson GD, Andersson TL, Pfeffer MA, Ellenberg SS. Data Monitoring Committees: Promoting Best Practices to Address Emerging Challenges. *Clin Trials*. 2017; Jan 1:1740774516688971. [Epub ahead of print]. PMID: 28135837.
2. Hess CN, **Roe MT**. Treatment of Coronary Artery Disease in Cancer Survivors: An Emerging Challenge. *Coron Artery Dis*. 2017;28(1):1-2. PMID: 27776090.
3. Roswell RO, Kunkes J, Chen AY, Chiswell K, Iqbal S, **Roe MT**, Bangalore S. Impact of Sex and Contact-to-Device Time on Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction-Findings From the National Cardiovascular Data Registry. *J Am Heart Assoc*. 2017;6(1). PMID: 28077385.
4. Masoudi FA, Ponirakis A, deLemos JA, Jollis JG, Kremers M, Messenger JC, Moore JW, Moussa I, Oetgen WJ, Varosy PD, Vincent RN, Wei J, Curtis JP, **Roe MT**, Spertus JA. Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. *J Am Coll Cardiol*. (2017), doi: 10.1016/j.jacc.2016.12.004. PMID: 28025065.
5. Østergaard L, Fosbøl EL, **Roe MT**. The Role of Antiplatelet Therapy in Primary Prevention. A Review. *Curr Pharm Des*. 2016 [Epub ahead of print.] PMID: 27917712.
6. Secemsky EA, Kirtane A, Bangalore S, Jovin IS, Shah RM, Ferro EG, Wimmer NJ, **Roe MT**, Dai D, Mauri L, Yeh RW. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. *JACC Cardiovasc Interv*. 2016;9(23):2376-86. PMID: 27838271.
7. Welsh RC, **Roe MT**, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. A Critical Reappraisal of Aspirin for Secondary Prevention in Patients with Ischemic Heart Disease. *Am Heart J*. 2016;181:92-100. PMID: 27823698.
8. Cornel JH, Ohman EH, Neely B, Jakubowski JA, Bhatt DL, White HD, Ardissino D, Fox KA, Prabhakaran D, Armstrong PW, Erlinge D, Tantry US, Gurbel PA, **Roe MT**. Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment with Dual Antiplatelet Therapy for Medically Managed Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. *J Am Heart Assoc*. 2016;5(11). PMID: 27815268.

9. Fordyce CB, **Roe MT**, Dickert NW. Maximizing Value and Minimizing Barriers: Patient-Centered Community Consultation for Research in Emergency Settings. *Clin Trials*. 2016 [Epub ahead of print.] PMID: 27798377.
10. Rymer JA, Harrison RW, Dai D, **Roe MT**, Messenger JC, Anderson JV, Peterson ED, Wang TY. Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥ 65 Years (from the CathPCI Registry). *Am J Cardiol*. 2016;118(7):959-66. PMID: 27614853.
11. Kontos MC, Wang TY, Chen AY, Bates ER, Dauerman HL, Henry TD, Manoukian SV, **Roe MT**, Suter R, Thomas L, French WJ. The Effect of High-Risk ST Elevation Myocardial Infarction Transfer Patients on Risk-Adjusted In-Hospital Mortality: A Report from the American Heart Association Mission: Lifeline Program. *Am Heart J*. 2016;180:74-81. PMID: 27659885.
12. Jones WS, **Roe MT**, Antman EM, Pletcher MJ, Harrington RA, Rothman RL, Oetgen WJ, Rao SV, Krucoff MW, Curtis LH, Hernandez AF, Masoudi FA. The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. *J Am Coll Cardiol*. 2016;68(17):1898-1907. PMID: 27765193.
13. Ahmad ZS, Andersen RL, Andersen LH, O'Brien EC, Kindt I, Shrader P, Vasandani C, Newman CB, deGoma EM, Baum SJ, Hemphill LC, Hudgins LC, Ahmen CD, Jullo IJ, Gidding SS, Duffy D, Neal W, Wilemon K, **Roe MT**, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. *J Clin Lipidol*. 2016;10(5):1223-9. PMID: 27678440.
14. Motivala AA, Parikh V, **Roe MT**, Dai D, Abbott JD, Prasad A, Mukherjee D. Predictors, Trends, and Outcomes (Among Older Patients ≥ 65 Years of Age) Associated with Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights from the NCDR Registry. *JACC Cardiovasc Interv* 2016;9(16):1639-48. PMID: 27539683.
15. Jing M, Gao F, Chen Q, de Carvalho LP, Sim LL, Koh TH, Foo D, Ong HY, Tong KL, Tan HC, Yeo TC, **Roe MT**, Chua T, Chan MY. Comparison of Long-Term Mortality of Patients Aged ≤ 40 Versus >40 Years With Acute Myocardial Infarction. *Am J Cardiol*. 2016;118(3):319-25. PMID: 27328956.
16. Motivala AA, Parikh V, **Roe MT**, Dai D, Abbott JD, Prasad A, Mukherjee D. Predictors, Trends, and Outcomes (Among Older Patients ≥ 65 Years of Age) Associated with Beta-Blocker Use in Patients with Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights from NCDR Registry. *JACC Cardiovasc Interv*. 2016;9(16):1639-48. PMID: 27539683.
17. Kaul P, Ohman EM, Knight JD, Anstrom KJ, **Roe MT**, Boden WE, Hochman JS, Gasparovic V, Armstrong PW, McCollam P, Fakhouri W, Cowper P, Davidson-Ray L, Clapp-Channing N, White HD, Fox KA, Prabhakaran D, Mark DB, TRILOGY ACS Investigators. Health-related Quality of Life Outcomes with Prasugrel Among Medically Managed Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) Trial. *Am Heart J*. 2016;178:55-64. PMID: 27502852.
18. Patel MR, Armstrong PW, Bhatt DL, Braunwald E, Camm AJ, Fox KAA, Harrington RA, Hiatt WR, James SK, Kirtane AJ, Leon MB, Lincoff AM, Mahaffey KW, Mauri L, Mehran R, Mehta SR, Montalescot G, Nicholls SJ, Perkovic V, Peterson ED, Pocock SJ, **Roe MT**, Sabatine MS, Sekeres M, Solomon SD, Steg G, Stone GW, Van de Werf F, Wallentin L, White HD, Gibson CM. Sharing Data from Cardiovascular Clinical Trials – A Proposal. Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies—Cardiovascular (ACCESS CV). *N Eng J Med*. 2016;375(5):407-9. PMID: 27518659.

19. Vora AN, Wang TY, Hellkamp AS, Thomas L, Henry TD, Goyal A, **Roe MT**. Differences in Short-and Long-Term Outcomes Among Older Patients with ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. *Circ Cardiovasc Qual Outcomes*. 2016;9(5):513-22. PMID: 27601458.
20. Wayangankar SA, **Roe MT**, Chen AY, Gupta RS, Giugliano RP, Newby LK, de Lemos JA, Alexander KA, Sanborn TA, Saucedo JF. Trends in use of Anti-Thrombotic Agents and Outcomes in Patients with Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) Managed with an Invasive Strategy. *Indian Heart J*. 2016;68(4):464-72. PMID: 27543467.
21. Chin CT, Boden WE, **Roe MT**, Neely B, Neely ML, Leiva-Pons JL, Corbalan R, Gottlieb S, Dalby AJ, Armstrong PW, Prabhakaran D, Fox KA, White HD, Ohman EM, Winters KJ, Schiele F. Effect of Prior Clopidogrel Use on Outcomes in Medically Managed Acute Coronary Syndrome Patients. *Heart*. 2016;102(15):1221-9. PMID: 27030601.
22. Fanaroff AC, **Roe MT**. Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. *Drug Safety*. 2016;39(8):715-27. PMID: 27028617.
23. Jackson LR 2nd, Piccini JP, Cyr DD, **Roe MT**, Neely ML, Martinez F, Luscher TF, Lopes RD, Winters KJ, White HD, Armstrong PW, Fox KA, Prabhakaran D, Bhatt DL, Ohman ME, Corbalan R. Dual Antiplatelet Therapy and Outcomes in Patients with Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights from the TRILOGY ACS Trial. *Clin Cardiol*. 2016;39(9):497-506. PMID: 27468086.
24. Hagstrom E, **Roe MT**, Hafley G, Neely ML, Sidhu MS, Winters KJ, Prabhakaran D, White HD, Armstrong PW, Fox KA, Ohman EM, Boden WE, TRILOGY ACS Investigators. Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients with Acute Coronary Syndrome Treated without Revascularization: Insights from the TRILOGY ACS Trial. *Clin Cardiol*. 2016;39(6):329-37. PMID: 27177240.
25. deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, **Roe MT**, Rader DJ, Ballantyne CMe, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles, JW. Treatment Gaps in Adults with Heterozygous Familial Hypercholesterolemia in the United States: Data from the CASCADE-FH Registry. *Circ Cardiovasc Genet*. 2016;9(3):240-9. PMID: 27013694.
26. Anderson LL, Dai D, Miller AL, **Roe MT**, Messenger JC, Wang TY. Percutaneous Coronary Intervention for Older Adults Who Present with Syncope and Coronary Artery Disease? Insights from the National Cardiovascular Data Registry. *Am Heart J*. 2016;176:1-9. PMID: 27264214.
27. Yerokun BA, Williams JB, Gaca J, Smith PK, **Roe MT**. Indications, Algorithms, and Outcomes for Coronary Artery Bypass Surgery in Patients with Acute Coronary Syndromes. *Coron Artery Dis*. 2016;27(4):319-26. PMID: 26945187.
28. Xu, J, Li W, Yang J, Wiviott SD, Sabatine MS, Peterson ED, Xian Y, **Roe MT**, Zhao W, Wang T, Tang X, Jia X, Wu Y, Gao R, Yang Y, CAMI Registry Study Group. The China Acute Myocardial Infarction (CAMI) Registry: A National Long-Term Registry-Research-Education Integrated Platform for Exploring Acute Myocardial Infarction in China. *Am Heart J*. 2016;175:193-201. PMID: 27179740.

29. Mathews R, Fonarow GC, Li S, Peterson ED, Rumsfeld JS, Heidenreich PA, **Roe MT**, Oetgen WJ, Jollis JG, Cannon CP, de Lemos JA, Want TY, National Cardiovascular Data Registry. *Am Heart J.* 2016; 175:1-8. PMID: 27179718.
30. Pandey A, McGuire DK, de Lemos JA, Das SR, Bery JD, Brilakis ES, Banerjee S, Marso SP, Barsness GW, Simon DN, **Roe MT**, Goyal A, Kosiborod M, Amsterdam EA, Kumbhani DJ. Revascularization Trends in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting with Non-ST Elevation Myocardial Infarction: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG). *Circ Cardiovasc Qual Outcomes* 2016;9(3):197-205. PMID: 27166210.
31. Chin CT, Neely B, Ohman EB, Armstrong PW, Corbalan R, White HD, Prabhakaran D, Winters KJ, Fox KA, **Roe MT**. Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndrome: Results from the TRILOGY ACS Trial. *Stroke.* 2016;47(4):1135-9. PMID: 26883498.
32. Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, **Roe MT**, Ohman EM, Harrington RA, Alexander JH, White HD, Van de Werf F, Piccini JP, Held C, Aylward PE, Moliterno DJ, Mahaffey KW, Tricoci P. Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. *JAMA Cardiol.* 2016;1(1):73-9. PMID: 27437658.
33. Vora AN, Peterson ED, McCoy LA, Garratt KN, Kutcher MA, Marso SP, **Roe MT**, Messenger JC, Rao SV. The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry CathPCI Registry. *JACC Cardiovasc Interv.* 2016;9(8):771-9. PMID: 27101904.
34. Wimmer NJ, Secemsky EA, Mauri L, **Roe MT**, Saha-Chaudhuri P, Dai D, McCabe JM, Resnic FS, Gurm HS, Yeh RW. *Circ Cardiovasc Interv.* 2016;9(4):e003464. PMID: 27059685.
35. Povsic TJ, **Roe MT**, Ohman EM, Steg PG, Stefan J, Plotnikov A, Muldl H, Welsh R, Bode C, Gibson CM. A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study. *Am Heart J.* 2016;174:120-8. PMID: 26995378.
36. Doll JA, Neely ML, **Roe MT**, Armstrong PW, White HD, Prabhakaran D, Winters KJ, Duwuru S, Sundseth SS, Jakubowski JA, Gurbel PA, Bhatt DL, Ohman EM, Fox KA, TRILOGY ACS Investigators. Impact of CYP2C19 Metabolizer Status on Patients with ACS Treated with Prasugrel Versus Clopidogrel. *J Am Coll Cardiol.* 2016;67(8):936-47. PMID: 26916483.
37. Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KA, Armstrong PW, **Roe MT**. Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. *J Am Coll Cardiol.* 2016;67(11):1298-97. PMID: 26988949.
38. Hess CN, Hellkamp AS, **Roe MT**, Thomas L, Scirica BM, Peng SA, Peterson ED, Wang TY. Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients with Non-ST-Segment Elevation Myocardial Infarction Discharged without in-hospital Revascularization. *J Am Heart Assoc.* 2016;5(3). PMID: 26976877.
39. Vora AN, Dai D, Gurm H, Amin AP, Messenger JC, Mahmud E, Mauri L, Wang TY, **Roe MT**, Curtis J, Patel MR, Dauerman HL, Peterson ED, Rao SV. Temporal Trends in the Risk Profile of Patients Undergoing Outpatient

Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry's CathPCI Registry. *Circ Cardiovasc Interv.* 2016;9(3):e003070.. PMID: 26957417.

40. Wayangankar SA, Bangalore S, McCoy LA, Jneid H, Latif F, Karrowni W, Charitakis K, Feldman DN, Dakik HA, Mauri L, Peterson ED, Messenger J, **Roe MT**, Mukherjee D, Klein A. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report from the Cath PCI Registry. *JACC Cardiovasc Interv.* 2016;9(4):341-51. PMID: 26803418.
41. Wang TY, McCoy LA, Bhatt DL, Rao SV, **Roe MT**, Resnic FS, Cavender MA, Messenger JC, Peterson ED. Multivessel vs Culprit-Only Percutaneous Coronary Intervention Among Patients 65 Years or Older with Acute Myocardial Infarction. *Am Heart J.* 2016;172:9-18. PMID: 26856210.
42. **Roe MT**, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM, TRILOGY ACS Investigators. Ascertainment, Classification, and Impact of Neoplasm Detection During Prolonged Treatment with Dual Antiplatelet Therapy with Prasugrel vs Clopidogrel Following Acute Coronary Syndrome. *Eur Heart J.* 2016;37:412-22. PMID: 26637834
43. Kang HJ, Simon D, Wang TY, Alexander KP, Jeong MH, Kim HS, Bates ER, Henry TD, Peterson ED, **Roe MT**. The Contemporary Use of Angiography and Revascularization Among Patients with Non-ST-Segment Elevation Myocardial Infarction in the United States Compared with South Korea. *Clin Cardiol.* 2015;38(12):708-14. PMID: 26782938
44. Kohsaka S, Miyata H, Ueda I, Masoudi FA, Peterson ED, Maekawa Y, Kawamura A, Fuuda K, **Roe MT**, Rumsfeld JS. An International Comparison of Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio Interhospital Cardiovascular Studies (JCD-KiCS). *Am Heart J.* 2015;170(6):1077-85. PMID: 26678628
45. Shen L, Shah BR, Li S, Thomas L, Wang TY, Alexander KP, Peterson ED, He B, **Roe MT**. The Association of Transfer Rate from Hospitals without Revascularization Capabilities and Mortality Risk for Older Non-ST-Segment Elevation Myocardial Infarction Patients. *Clin Cardiol.* 2015;38(12):733-9. PMID: 26511331
46. Nicolau JC, Bhatt DL, **Roe MT**, Lokhnygina Y, Neely B, Corbalan R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FW, Armstrong PW, White HD, Fox KA, Prabhakaran D, Ohman EM, TRILOGY ACS Investigators. Concomitant Proton-Pump Inhibitor Use, Platelet Activity, and Clinical Outcomes in Patients with Acute Coronary Syndromes Treated with Prasugrel versus Clopidogrel and Managed without Revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes Trial. *Am Heart J.* 2015;170(4):683-94. PMID: 26386792
47. Clemmensen, P, **Roe, MT**, Hochman JS, Cyr DD, Neely ML, McGuire DK, Cornel JH, Huber K, Zamoryakhin D, White HD, Armstrong PW, Fox KA, Prabhakaran D, Ohman EM, TRILOGY ACS Investigators. Long-term Outcomes for Women Versus Men with Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction Managed Medically without Revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal strategy to medically Manage Acute Coronary Syndromes Trial. *Am Heart J.* 2015;170:695-705. PMID: 26386793.
48. Melloni C, **Roe MT**. Cardiac Troponin and Risk Stratification in Ischemic Heart Disease. *N Engl J Med.* 2015;373:672-4. PMID: 26267628.

49. Melloni C, Cornel JH, Hafley G, Neely ML, Clemmensen P, Zamoryakhin D, Prabhakaran D, White HD, Fox KA, Ohman EM, Armstrong PW, **Roe MT**. Impact of Chronic Kidney Disease on Long-Term Ischemic and Bleeding Outcomes in Medically Managed Patients with Acute Coronary Syndromes: Insights from the TRILOGY ACS Trial. *Eur Heart J Acute Cardiovasc Care*. 2016;5(6):443-454. PMID: 26228448.
50. Hess CN, **Roe MT**, Clare RM, Chiswell K, Kelly J, Tcheng JE, Hagstrom E, James SK, Khouri MG, Hirsch BR, Kong DF, Abernethy AP, Krucoff MW. Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. *J Am Heart Assoc*. 2015;6:4(7). PMID: 26150477.
51. Mahaffey KW, Hager R, Wojdyla D, White HD, Armstrong PW, Alexander JF, Tricoci P, Ionescu RD, Ohman EM, **Roe MT**, Harrington RA, Wallentin L. Meta-analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. *J Am Heart Assoc*. 2015;18:4(6). PMID: 26089177.
52. Dauerman HL, Bates ER, Kontos MC, Shuang L, Garvey JL, Henry TD, Manoukian SV, **Roe MT**. Nationwide Analysis of Patients with ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention. *Circ Cardiovasc Inter* 2015;8(5):e002450. PMID: 25901044.
53. Aragam KG, Dai D, Neely ML, Bhatt DL, **Roe MT**, Rumsfeld JS, Gurm HS. Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. *J Am Coll Cardiol*. 2015;65(19):2079-88. PMID: 25975470.
54. Anderson LL, French WJ, Peng SA, Vora AN, Henry TD, **Roe MT**, Kontos MC, Granger CB, Bates ER, Hellkamp A, Wang TY. Direct Transfer from the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry. *Circ Cardiovasc Inter*. 2015;8:e3002477. PMID: 26338881.
55. Xu H, Li W, Yang J, Wiviott SD, Sabatine MS, Peterson ED, Xian Y, **Roe MT**, Zhao W, Wang T, Tang X, Jia X, Wu Y, Gao R, Yang Y. The China Acute Myocardial Infarction (CAMI) Registry: A National Long-term Registry-Research-Education Integrated Platform for Exploring Acute Myocardial Infarction in China. *Am Heart J*. 2016;175:193-201. PMID: 27179740.
56. **Roe MT**, Mahaffey KW, Ezekowitz JA, Alexander JH, Goodman SG, Hernandez A, Temple T, Berdan L, Califf RM, Harrington RA, Peterson ED, Armstrong PW. The Future of Cardiovascular Clinical Research in North America and Beyond – Addressing Challenge and Leveraging Opportunities Through Unique Academic and Grassroots Collaborations. *Am Heart J*. 2015;169:743-50. PMID: 26027610
57. Kontos MC, Scirica BM, Chen AY, Thomas L, Anderson ML, Diercks DB, Jollis JG, **Roe MT**. Cardiac Arrest and Clinical Characteristics, Treatments and Outcomes Among Patients Hospitalized with ST-Elevation Myocardial Infarction in Contemporary Practice: A Report from the National Cardiovascular Data Registry. *Am Heart J*. 2015;169:515-522. PMID: 25819858.
58. Alfredsson J, **Roe MT**. Risks and Benefits of Triple Oral Anti-Thrombotic Therapies after Acute Coronary Syndromes and Percutaneous Coronary Intervention. *Drug Safety*. 2015;38(5):481-91. PMID: 25829216.
59. Fordyce CB, **Roe MT**, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular Drug Development: Is it Dead or Just Hibernating? *J Am Coll Cardiol*. 2015;65:1567-82. PMID: 25881939.

60. White HD, Westerhout CM, Alexander KP, **Roe MT**, Winters KJ, Cyr DD, Fox KA, Prabhakaran D, Hochman JS, Armstrong PW, Ohman EM; TRILOGY ACS Investigators. Frailty is Associated with Worse Outcomes in non-ST-segment Elevation Acute Coronary Syndromes: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) Trial. *Eur Heart J Acute Cardiovasc Care*. 2016;5(3):231-42. PMID: 25897147.
61. Alfredsson J, **Roe MT**. Balancing the Risks and Benefits of Long-Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications. *J Am Heart Assoc*. 2015;4:e001897. PMID: 25792126.
62. O'Brien EC, Simon DN, **Roe MT**, Wang TY, Peterson ED, Alexander KP. Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients with Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). *Am J Cardiol*. 2015;115(12):1655-60. PMID: 25888303.
63. Doll JA, **Roe MT**. Time to Treatment as a Quality Metric for Acute STEMI Care. *Lancet* 2015;385:1056-7. PMID: 25467572.
64. Mehta RH, Chen AY, Alexander KP, Phman EM, **Roe MT**, Peterson ED. Doing the Right Things and Doing Them the Right Way: Association between Hospital Guideline Adherence, Dosing Safety, and Outcomes among Patients with Acute Coronary Syndrome. *Circulation*. 2015;131:980-7. PMID: 25688146.
65. Vora AN, Holmes DN, Rokos I, **Roe MT**, Granger CB, French WJ, Antman E, Henry RD, Thomas L, Bates ER, Wang TY. Fibrinolysis Use among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care: A Report from the US National Cardiovascular Data Registry. *JAMA Inter Med*. 2015;175:207-15. PMID: 25485876.
66. Roy A, **Roe MT**, Neely ML, Cyr DD, Zamoryakhin D, Fox KA, White HD, Armstrong PW, Ohman EM, Prabhakaran D. Impact of Human Development Index on the Profile and Outcomes of Patients with Acute Coronary Syndrome. *Heart*. 2015;101:279-86. PMID: 25538134.
67. Hall TS, Hallén J, Krucoff MW, **Roe MT**, Brennan DM, Agewall S, Atar D, Lincoff AM. Cardiac Troponin I for Prediction of Clinical Outcomes and Cardiac Function Through 3-month Follow-up after Primary Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction. *Am Heart J*. 2015;169:257-65. PMID: 25641535.
68. Lopes RD, Gharacholou SM, Holmes DN, Thomas L, Wang TY, **Roe MT**, Peterson ED, Alexander KP. Cumulative Incidence of Death and Rehospitalization among the Elderly in the First Year after NSTEMI. *Am J Med*. 2015;128;6:582-90. PMID: 25660246.
69. Yeh RW, Czarney MJ, Normand SL, Kereiakes DJ, Holmes DR Jr, Brindis RG, Weaver WD, Rumsfeld JS, **Roe MT**, Kim S, Deisboll-Shempp P, Mauri L. Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet Therapy Study versus the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2015;8(1):96-102. PMID: 25399845.
70. Nicholson BD, Shindia HS, **Roe MT**, Chen AY, Jollis JG, Kontos MC. Relationship of the Distance Between Non-PCI Hospitals and Primary PCI Centers, Mode of Transport and Reperfusion Time Among Ground and Air Interhospital Transfers Using NCDR's ACTION Registry-GWTG: A Report from the American Heart Association Mission: Lifeline Program. *Circ Cardiovasc Interv*. 2014;7:797-805. PMID: 25406204.

71. Kontos MC, Rennyson SL, Chen AY, Alexander KP, Peterson ED, **Roe MT**. The Association of Myocardial Infarction Process of Care Measures and In-hospital Mortality: A Report from the NCDR. *Am Heart J*. 2014;168:766-75. PMID: 25440806.
72. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, **Roe MT**, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of Alirocumab, a Monoclonal Antibody to PCSK9, on Long-term Cardiovascular Outcomes Following Acute Coronary Syndromes: Rationale and Design of the ODYSSEY Outcomes Trial. *Am Heart J*. 2014;168:682-9. PMID: 25440796.
73. Harskamp RE, **Roe MT**. Soluble Urokinase-type Plasminogen Activator Receptor: A Useful Biomarker for Coronary Artery Disease and Clinical Outcomes. *J Am Heart Assoc*. 2014;3:e001431. PMID: 25341888.
74. Bagai A, Schulte PJ, Granger CB, Mahaffey KW, Christenson RH, Bell G, Lopes RD, Green CL, Lincoff AM, Armstrong PW, **Roe MT**. Prognostic Implications of Creatine Kinase-MB Measurements in ST-segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention. *Am Heart J*. 2014;168:503-11. PMID: 25262260.
75. Rousan TA, Pappay RN, Chen AY, **Roe MT**, Saucedo JF. Impact of Diabetes Mellitus on Clinical Characteristics, Management, and In-hospital Outcomes in Patients with Acute Myocardial Infarction (from the NCDR). *Am J Cardiol*. 2014;114:1136-44. PMID: 25150136.
76. McNamara RL, Chung SC, Jernberg T, Holmes D, **Roe MT**, Timmis A, James S, Deanfield J, Fonarow GC, Peterson ED, Jeppsson A, Hemingway H. International Comparisons of the Management of Patients with Non-ST-Segment Elevation Acute Myocardial Infarction in the United Kingdom, Sweden and the United States: The MINASP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR Registries. *Int J Cardiol*. 2014;175:240-7. PMID: 24882696.
77. Udell JA, Wang TY, Li S, Kohli P, **Roe MT**, de Lemos JA, Wiviott SD. Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry. *JAMA*. 2014;312:841-3. PMID: 25157729.
78. Hall HM, de Lemos JA, Enriquez JR, McGuire DK, Peng SA, Alexander KP, **Roe MT**, Desai N, Wiviott SD, Das SR. Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results from the National Cardiovascular Data Registry (NCDR). *Circ Cardiovasc Qual Outcomes*. 2014;5:701-7. PMID: 25116897.
79. Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, Cheema AN, Peterson ED, Saucedo JF, Granger CB, **Roe MT**, Bhatt DL, McNamara RL, Alexander KP. In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients with Acute Myocardial Infarction Treated with Percutaneous Coronary Intervention: Insights Into Contemporary Practice from the National Cardiovascular Data Registry. *Circ Cardiovasc Inter*. 2014;7:585-93. PMID: 25097196.
80. Hess CN, **Roe MT**, Gibson CM, Temple JR, Pencina MJ, Zarin DA, Anstrom KJ, Alexander JH, Sherman RE, Fiedorek FT, Mahaffey KW, Lee KL, Chow SC, Armstrong PW, Califf RM. Independent Data Monitoring Committees: Preparing a Path for the Future. *Am Heart J*. 2014;168:135-41. PMID: 25066551.
81. Ahmad T, **Roe MT**. Acute Coronary Syndromes: Treatment for Low-Risk Patients with STEMI -Challenges Remain. *Nat Rev Cardiol*. 2014;8:440-42. PMID: 24958076.
82. Dasari TW, **Roe MT**, Chen AY, Peterson ED, Giugliano RP, Fonarow GC, Saucedo JF. Impact of Time of Presentation on Process Performance and Outcomes in ST-Segment-Elevation Myocardial Infarction: A

Report from the American Heart Association: Mission Lifeline Program. *Circ Cardiovasc Qual Outcomes*. 2014;5:656-63. PMID: 25074371.

83. Bakal JA, **Roe MT**, Ohman EM, Goodman SG, Fox KA, Zheng Y, Westerhout CM, Hochman JS, Lokhnygina Y, Brown EB, Armstrong PW. Applying Novel Methods to Assess Clinical Outcomes: Insights from the TRILOGY ACS Trial. *Eur Heart J*. 2015;36(6):385-92. PMID: 25012156.
84. Cotoni DA, **Roe MT**, Li S, Kontos MC. Frequency of Nonsystem Delays in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention and Implications for Door-to Balloon Time Reporting (from the American Heart Association Mission: Lifeline Program). *Am J Cardiol*. 2014;114:24-8. PMID: 24819905.
85. Cornel JH, Ohman EM, Neely B, Clemmensen P, Sritara P, Zamoryakhin D, Armstrong PW, Prabhakara D, White HD, Fox KA, Gurbel PA, **Roe MT**. Impact of Smoking Status on Platelet Function and Clinical Outcomes with Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndromes Managed without Revascularization: Insights from the TRILOGY ACS Trial. *Am Heart J*. 2014;168:76-87. PMID: 24952863.
86. Mathews R, Chen A, Thomas L, Wang TY, Chin CT, Thomas KL, **Roe MT**, Peterson ED. Differences in Short-term Versus Long-term Outcomes of Older Black versus White Patients with Myocardial Infarction: Findings from CRUSADE. *Circulation*. 2014;130:659-67. PMID: 25002016.
87. Patel MR, Dai D, Hernandez AF, Douglas PS, Messenger J, Garratt KN, Maddox TM, Peterson ED, **Roe MT**. Prevalence and Predictors of Nonobstructive Coronary Artery Disease Identified with Coronary Angiography in Contemporary Clinical Practice. *Am Heart J*. 2014;167:846-52. PMID: 24890534.
88. **Roe MT**, Sherwood MW. Uncovering the Shroud on Antiplatelet Therapy for Patients with ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol Cardiovasc Interv*. 2014;7:613-14. PMID: 24947720.
89. Shen L, Shah BR, Nam A, Holmes D, Alexander KP, Bhatt DL, Ho PM, Peterson ED, He B, **Roe MT**. Implications of Prior Myocardial Infarction for Patients Presenting with an Acute Myocardial Infarction. *Am Heart J*. 2014;167:840-45. PMID: 24890533.
90. Wang TY, Magid DJ, Ting HH, Li S, Alexander KP, **Roe MT**, Peterson ED. The Quality of Antiplatelet and Anticoagulant Medication Administration Among ST-Segment Elevation Myocardial Infarction Patients. Transferred for Primary Percutaneous Coronary Intervention. *Am Heart J*. 2014;167:833-39. PMID: 24890532.
91. Lincoff AM, **Roe MT**, Aylward P, Galla J, Rynkiewicz A, Guetta V, Szelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Foster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M, for the PROTECTION AMI Investigators. Inhibition of Delta-Protein Kinase C by Delcasertib as an Adjunct to Primary Percutaneous Coronary Intervention for Acute Anterior ST-segment Elevation Myocardial Infarction: Results of the PROTECTION-AMI Randomized Controlled Trial. *Eur Heart J*. 2014;35:2516-23. PMID: 24796339.
92. O'Brien E, Subherwal S, **Roe MT**, Holmes DN, Thomas L, Alexander KP, Wang TY, Peterson ED. Do Patients Treated at Academic Hospitals Have Better Longitudinal outcomes after Admission for Non-ST-Elevation Myocardial Infarction? *Am Heart J*. 2014;167:762-69. PMID: 24676988.

93. Sherwood MW, Wiviott SD, Peng SA, **Roe MT**, DeLemos J, Peterson ED, Wang TY. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry. *J Am Heart Assoc.* 2014;2:e000849. PMID: 24732921.
94. O'Brien EC, Fosbol EL, Peng A, Alexander KP, **Roe MT**, Peterson ED. Association of Body Mass Index and Long-Term Outcomes in Older Patients with Nono-ST-Segment-Elevation Myocardial Infarction: Results From the CRUSADE Registry. *Circ Cardiovasc Qual Outcomes.* 2014;7:102-9. PMID: 24326936.
95. Xian Y, Chen AY, Thomas L, **Roe MT**, Subherwal S, Cannon CP, Pollack CV, Fonarow GC, Kosiborod M, Peterson D, Alexander KP. Sources of Hospital-Level Variation in Major Bleeding Among Patients with Non-ST-Segment Elevation Myocardial Infarction: A Report From the National Cardiovascular Data Registry (NCDR). *Circ Cardiovasc Qual Outcomes.* 2014;7:236-43. PMID: 24594548.
96. Kang HJ, **Roe MT**. Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease. *J Cardiovasc Trans Res.* 2014;7:112-22. PMID: 24464592.
97. O'Brien EC, **Roe MT**, Fauro ES, Peterson ED, Ballantyne CM, Genest J, Gidding SS, Hammond E, Hemphill LC, Hudgins LC, Kindt I, Moriarity PM, Ross J, Underberg JA, Watson K, Pickhardt D, Rader DJ, Wilemon K, Knowles JW. Rationale and Design of the Familial Hypercholesterolemia Foundation of CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia Registry. *Am Heart J.* 2014;167:342-49. PMID: 24576518.
98. Harskamp RE, Wang TY, Bhatt DL, Wiviott SD, Amsterdam EA, Li S, Thomas L, de Winter RJ, **Roe MT**. Hospital Patterns of Medical Management Strategy Use for Patients with Non-ST-Elevation Myocardial Infarction and 3-Vessel or Left Main Coronary Artery Disease. *Am J Heart.* 2014;167:355-63. PMID: 24576520.
99. Patel JH, Gupta R, **Roe MT**, Peng SD, Wiviott SD, Saucedo JF. Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients with Non-ST-Segment Elevation Myocardial Infarction. *Am J Cardiol.* 2014;113:256-61. PMID: 24290492.
100. Gupta N, Kontos MC, Gupta A, Dai D, Vetrovec GW, **Roe MT**, Messenger, J. Characteristics and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Following Cardiac Arrest (from the NCDR). *Am J Cardiol.* 2014;113:1087-92. PMID: 24513475.
101. Chin CT, Messenger JC, Dai D, McCoy LA, Kutcher MA, Anderson HV, **Roe MT**, Wang TY. Comparison of Percutaneous Coronary Intervention for Previously Treated Versus de novo Culprit Lesions in Acute Myocardial Infarction Patients: Insights from the National Cardiovascular Data Registry. *Am Heart J.* 2014;167(3):393-400. PMID: 24576525.
102. van Diepen S, Chen AY, Wang TY, Alexander KP, Ezekowitz JA, Peterson ED, **Roe MT**. Influence of Heart Failure Symptoms and Ejection Fraction on Short-and Long Term Outcomes for Older Patients with non-ST-segment Elevation Myocardial Infarction. *Am Heart J.* 2014;167:267-73. PMID: 24439989.
103. Shavelle DM, Chen AY, Matthew RV, **Roe MT**, de Lemos JA, Jollis J, Thomas JL, French WJ, ACTION-GWTG Investigators. Predictors of Reperfusion Delay in Patients with ST Elevation Myocardial Infarction Self-Transported to the Hospital (from the American Heart Association's Mission: Lifeline Program). *Am J Cardiol.* 2014;113:798-80. PMID: 24393257.

104. Gupta N, Washam JB, Mountantonakis SE, Li S, **Roe MT**, de Lemos JA, Arora R. Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). *Am J Cardiol.* 2014;113:749-56. PMID: 24388623.
105. Chin CT, Wang TY, Chen AY, Matthew R, Alexander KP, **Roe MT**, Peterson ED. Trends in outcomes among older patients with non-ST-segment elevation myocardial infarction. *Am Heart J.* 2014;167:36-42. PMID: 24332140.
106. Shen L, Peterson ED, Li S, Thomas L, Alexander K, Xian Y, Wang TY, **Roe MT**, He B, Shah BR. The association between smoking and long-term outcomes after non-ST-segment elevation myocardial infarction in older patients. *Am Heart J.* 2013;166:1056-62. PMID: 24268221.
107. Xu W, Holmes DN, Becker RC, **Roe MT**, Peterson ED, Wang TY. Comparison of long-term outcomes between older Asian and white patient with non-ST-segment elevation myocardial infarction: Findings from CRUSADE-CMS database. *Am Heart J.* 2013;166:1050-55. PMID: 24268220.
108. Desai NR, Peterson ED, Chen AY, Wiviott SD, Sabatine MS, Alexander KP, **Roe MT**, Shah BR. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients – a report from the National Cardiovascular Data Registry. *Am Heart J.* 2013;166:1043-49. PMID: 24268219.
109. Anderson ML, Peterson ED, Peng SA, Wang TY, Ohman EM, Bhatt DL, Saucedo JF, **Roe MT**. Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDR. *Circ Cardiovasc Qual Outcomes.* 2013;6:708-15. PMID: 24221834.
110. Wang TY, McCoy LA, Messenger JC, Neely ML, Ho KK, **Roe MT**, Anderson HV. Cardiac biomarker measurement after elective percutaneous coronary interventions in older patients: Insights from the National Cardiovascular Data Registry. *Am Heart J.* 2013;166:927-34. PMID: 24176450.
111. Fosbol EL, Wang TY, Li S, Piccini J, Lopes RD, Mills RM, Klaskala W, Thomas L, **Roe MT**, Peterson ED. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. *Am Heart J.* 2013;166:864-70. PMID: 24176442.
112. Masoudi FA, Ponirakis A, Yeh RW, Maddox TM, Beachy J, Casale PN, Curtis JP, DeLemos J, Fonarow G, Heidenreich P, Loutras C, Kremers M, Messenger J, Moussa I, Oetgen WJ, **Roe MT**, Rosenfield K, Shields TP Jr, Spertus JA, Wei J, White C, Young CH, Rumsfeld JS. Cardiovascular care facts: A report from the national cardiovascular data registry: 2011. *J Am Coll Cardiol.* 2013;62:1931-47. PMID: 24036027.
113. Acharjee S, **Roe MT**, Amsterdam EA, Holmes DN, Boden WE. Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). *Am J Cardiol.* 2013;112:1057-62. PMID: 23891245.
114. Hess CN, Shah BR, Peng SA, Thomas L, **Roe MT**, Peterson ED. Association of early physician follow-up and 30-day readmission after non-ST-segment elevation myocardial infarction among older patients. *Circulation.* 2013;128:1206-13. PMID: 23946265.
115. Peacock WF, Kontos MC, Amsterdam E, Cannon CP, Diercks D, Garvey L, Graff IV L, Holmes D, Holmes KS, McCord J, Newby K, **Roe MT**, Dadkhah S, Siler-Fisher A, Ross M. Impact of society of cardiovascular patient care accreditation on quality: An ACTION Registry® - Get With the Guidelines™ analysis. *Crit Pathways in Cardiol.* 2013;12:116-20. PMID: 23892940.

116. Wiviott SD, White HD, Ohman EM, Fox KAA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Levia-Pons J, Pavlides G, Winters KW, **Roe MT**, Bhatt DL. Prasugrel vs. clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. *Lancet*. 2013;382:605-13. PMID: 23953385
117. Borden WB, Spertus JA, Mushlin AI, **Roe MT**, McCoy LA, Redberg RF. Antianginal therapy before percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2013;4:436-43. PMID: 23922143.
118. **Roe MT**, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW. Elderly patients with acute coronary syndroms managed without revascularization insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel vs. standard-dose clopidogrel. *Circulation*. 2013;128:823-33. PMID: 23852610.
119. Bagai A, Jollis JG, Dauerman HL, Peng SA, Rokos IC, Bates ER, French WJ, Granger CB, **Roe MT**. Emergency department bypass for ST-segment elevation myocardial infarction patients identified with a pre-hospital electrocardiogram: A report from the American Heart Association Mission: Lifeline Program. *Circulation*. 2013;128:352-59. PMID: 23788525.
120. Bagai A, Chen AY, Wang TY, Alexander KP, Thomas L, Ohman EM, Hochman JS, Peterson ED, **Roe MT**. Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock. *Am Heart J*. 2013;166:298-304. PMID: 23895813.
121. **Roe MT**, Li S, Thomas L, Wang TY, Alexander KP, Ohman EM, Peterson ED. Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction. *Circ Cardiovasc Qual Outcomes*. 2013;6:323-32. PMID: 23652734.
122. Scirica BM, Kadakia MB, de Lemos JA, **Roe MT**, Morrow DA, Li S, Wiviott SD, Kontos MC; on behalf of the National Cardiovascular Data Registry. Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry(R)-GWTG. *Clin Chem*. 2013;59:1205-14. PMID: 23630179.
123. Subherwal S, Ohman EM, Mahaffey KW, Rao SV, Alexander JH, Wang TY, Alexander KP, Hasselblad V, **Roe MT**. Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches. *Am Heart J*. 2013;165:644-54. PMID: 23622901.
124. Anderson HV, Weintraub WS, Radford MJ, Kremers MS, **Roe MT**, Shaw RE, Pinchotti DM, Tcheng JE. Standardized cardiovascular data for clinical research, registries, and patient care: a report from the data standards workgroup of the national cardiovascular research infrastructure project. *J Am Coll Cardiol*. 2013;61:1835-46. PMID: 23500238.
125. Hanna EB, Alexander KP, Chen AY, **Roe MT**, Funk M, Saucedo JF. Characteristics and In-Hospital Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing an Invasive Strategy According to Hemoglobin Levels. *Am J Cardiol*. 2013;111:1099-103. PMID: 23453458.
126. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT Jr, Drozda JP Jr, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, **Roe MT**, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger

S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). *J Am Coll Cardiol.* 2013;61:992-1025. PMID: 23369353.

127. van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, **Roe MT**, Ezekowitz JA, Moliterno DJ, Neumann FJ, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P; on behalf of the APEX AMI Investigators. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. *Int J Cardiol.* 2013;168:2127-33. PMID: 23394896.
128. Gurbel PA, **Roe MT**, Jakubowski JA, Shah S, Erlinge D, Goodman SG, Huber K, Chan MY, Cornel JH, Tantry US, Ohman EM. Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? *Thromb Haemost.* 2012;108:12-20. PMID: 22627684.
129. Riley RF, Newby LK, Don CW, **Roe MT**, Holmes DN, Gandhi SK, Kutcher MA, Herrington DM. Diagnostic time course, treatment, and in-hospital outcomes for patients with ST-segment elevation myocardial infarction presenting with nondiagnostic initial electrocardiogram: A report from the American Heart Association Mission: Lifeline program. *Am Heart J* 2013;165:50-56. PMID: 23237133.
130. Enriquez JR, de Lemos JA, Parikh SV, Peng SA, Spertus JA, Holper EM, **Roe MT**, Rohatgi A, Das SR. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. *Am Heart J.* 2013;165:43-49. PMID: 23237132.
131. Leonardi S, Chen AY, Gharacholou SM, Wang TY, de Lemos JA, Saucedo JF, Peterson ED, **Roe MT**. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. *Am Heart J.* 2012;164:502-8. PMID: 23067907.
132. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, White HD, Fox KA, Prabhakaran D, Armstrong PW, Tantry US, **Roe MT**. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy. *JAMA.* 2012;4:1-10. PMID: 23117779.
133. Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, **Roe MT**, Wang TY; American College of Cardiology National Cardiovascular Data Registry. Incidence and Outcomes of No-reflow Phenomenon During Percutaneous Coronary Intervention among Patients with Acute Myocardial Infarction. *Am J Cardiol.* 2013;111:178-84. PMID: 23111142.
134. Vavalle JP, Lopes RD, Chen AY, Newby LK, Wang TY, Shah BR, Ho PM, Wiviott SD, Peterson ED, **Roe MT**, Granger CB. Hospital length of stay in patients with non-ST-segment elevation myocardial infarction. *Am J Med.* 2012;125:1085-94. PMID: 22921886.
135. Dehmer GJ, Weaver D, **Roe MT**, Milford-Beland S, Fitzgerald S, Hermann A, Messenger J, Moussa I, Garratt K, Rumsfeld J, Brindis RG. A Contemporary View of Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention in the United States: A Report From the CathPCI Registry of the National Cardiovascular Data Registry, 2010 Through June 2011. *J Am Coll Cardiol.* 2012;60:2017-31. PMID: 23083784.
136. **Roe MT**, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire

DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cintează M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med*. 2012;367:1297-309. PMID: 22920930.

137. Li Y, Tai BC, Sia W, Phua QH, Richards MA, Low A, Chan KH, Teo SG, Sim TB, Lee CH, **Roe MT**, Yeo TC, Tan HC, Chan MY. Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. *J Thromb Thrombolysis*. 2012;34:499-505. PMID: 22855283.
138. Eapen ZJ, Tang WH, Felker GM, Hernandez AF, Mahaffey KW, Lincoff AM, **Roe MT**. Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. *Circ Cardiovasc Qual Outcomes*. 2012;5:594-600. PMID: 22811505.
139. Parikh NI, Honeycutt EF, **Roe MT**, Neely M, Rosenthal EJ, Mittleman MA, Carrozza JP Jr, Ho KK. Left and Codominant Coronary Artery Circulations are Associated With Higher In-Hospital Mortality Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Report From the National Cardiovascular Database Cath Percutaneous Coronary Intervention (CathPCI) Registry. *Circ Cardiovasc Qual Outcomes*. 2012;5:775-82. PMID: 23110791.
140. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, Patel MR, Ohman EM, Gibler WB, Peterson ED, **Roe MT**. Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non-ST-Segment-Elevation Myocardial Infarction. *Circ Cardiovasc Qual Outcomes*. 2012;5:541-49. PMID: 22715460.
141. Subherwal S, Peterson ED, Dai D, Thomas L, Messenger JC, Xian Y, Brindis RG, Feldman DN, Senter S, Klein LW, Marso SP, **Roe MT**, Rao SV. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. *J Am Coll Cardiol*. 2012;59:1861-69. PMID: 22595404.
142. Fosbol EL, Wang TY, Li S, Piccini JP, Lopes RD, Shah B, Mills RM, Klaskala W, Alexander KP, Thomas L, **Roe MT**, Peterson ED. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. *Am Heart J*. 2011;163:720-28. PMID: 22520540.
143. Duffy D, Holmes DN, **Roe MT**, Peterson ED. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction. *Am Heart J*. 2012;163:705-13. PMID: 22520538.
144. Owan TE, **Roe MT**, Messenger JC, Dai D, Michaels AD. Contemporary use of adjunctive thrombectomy during primary percutaneous coronary intervention for ST-elevation myocardial infarction in the United States. *Catheter Cardiovasc Interv*. 2012;80:1173-80. PMID: 22511575.
145. Chin CT, Wang TY, Li S, Wiviott SD, Delemos JA, Kontos MC, Peterson ED, **Roe MT**. Comparison of the Prognostic Value of Peak Creatine Kinase-MB and Troponin Levels Among Patients With Acute Myocardial Infarction: A Report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. *Clin Cardiol*. 2012;35:424-29. PMID: 22434769.
146. Lopes RD, Subherwal S, Holmes DN, Thomas L, Wang TY, Rao SV, Magnus Ohman E, **Roe MT**, Peterson ED, Alexander KP. The association of in-hospital major bleeding with short-, intermediate-, and long-term

mortality among older patients with non-ST-segment elevation myocardial infarction. *Eur Heart J*. 2012;16:2044-53. PMID: 22396323.

147. **Roe MT**, White JA, Kaul P, Tricoci P, Lokhnygina Y, Miller CD, van't Hof AW, Montalescot G, James SK, Saucedo J, Ohman EM, Pollack CV Jr, Hochman JS, Armstrong PW, Giugliano RP, Harrington RA, Van de Werf F, Califf RM, Newby LK. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. *Circ Cardiovasc Qual Outcomes*. 2012;5:205-13. PMID: 22373905.
148. Subherwal S, Peterson ED, Chen AY, **Roe MT**, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, Lopes RD, Alexander KP, Wang TY. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. *Circulation*. 2012;125:1414-23. PMID: 22319105.
149. Fox CS, Muntner P, Chen AY, Alexander KP, **Roe MT**, Wiviott SD. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. *Circulation*. 2012;125:497-504. PMID: 22179533.
150. van Diepen S, **Roe MT**, Lopes RD, Stebbins A, James S, Newby LK, Moliterno DJ, Neumann FJ, Ezekowitz JA, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Theroux P, Granger CB. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. *J Thromb Thrombolysis*. 2012;34:106-13. PMID: 22307842.
151. Yeo KK, Li S, Amsterdam EA, Wang TY, Bhatt DL, Saucedo JF, Kontos MC, **Roe MT**, French WJ. Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). *Am J Cardiol*. 2012;109:497-501. PMID: 22152973.
152. Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED, **Roe MT**, de Lemos JA. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). *J Am Coll Cardiol*. 2011;58:2642-50. PMID: 22152950.
153. **Roe MT**, Ohman EM. A New Era in Secondary Prevention after Acute Coronary Syndrome. *N Engl J Med*. 2012;366:85-87. PMID: 22077849.
154. Melloni C, **Roe MT**, Chen AY, Wang TY, Wiviott SD, Ho PM, Peterson ED, Alexander KP. Use of Early Clopidogrel by Reperfusion Strategy among Patients Presenting With ST-Segment Elevation Myocardial Infarction. *Circ Cardiovasc Qual Outcomes*. 2011;4:603-9. PMID: 21988922.
155. **Roe MT**, Chen AY, Thomas L, Wang TY, Alexander KP, Hammill BG, Gibler WB, Ohman EM, Peterson ED. Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: The CRUSADE long-term mortality model and risk score. *Am Heart J*. 2011;162:875-83. PMID: 22093204.
156. Rao SV, Kaltenbach LA, Weintraub WS, **Roe MT**, Brindis RG, Rumsfeld JS, Peterson ED. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. *JAMA*. 2011;306:1461-67. PMID: 21972308.

157. Hanna EB, Chen AY, **Roe MT**, Wiviott SD, Fox CS, Saucedo JF. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. *J Am Coll Cardiol Cardiovas Interv*. 2011;4:1002-8. PMID: 21939940.
158. Brilakis ES, Rao SV, Banerjee S, Goldman S, Shunk KA, Holmes DR Jr, Honeycutt E, **Roe MT**. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients a report from the national cardiovascular data registry. *J Am Coll Cardiol Cardiovas Interv* 2011;4:844-50. PMID: 21851896.
159. Wang TY, Nallamothu BK, Krumholz HM, Li S, **Roe MT**, Jollis JG, Jacobs AK, Holmes DR, Peterson ED, Ting HH. Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. *JAMA*. 2011;305:2540-47. PMID: 21693742.
160. Mathews R, Peterson ED, Li S, **Roe MT**, Glickman SW, Wiviott SD, Saucedo JF, Antman EM, Jacobs AK, Wang TY. Use of Emergency Medical Service Transport Among Patients With ST-Segment-Elevation Myocardial Infarction: Findings From the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With the Guidelines. *Circulation*. 2011;124:154-63. PMID: 21690494.
161. James SK, **Roe MT**, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. *British Med J*. 2011;342:doi:10.1136/bmj.d3527. PMID: 21685437.
162. Don CW, **Roe MT**, Li S, Fraulo E, Pmerantsev E, Palacios I, Wiviott SD. Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. *Am Heart J*. 2011;161:689-97. PMID: 21473967.
163. Mahaffey KW, Pieper KS, Lokhnygina Y, Califf RM, Antman E, Kleiman NS, Goodman SG, White HD, Rao SV, Hochman JS, Cohen M, Col JJ, **Roe MT**, Ferguson JJ. The impact of postrandomization crossover of therapy in acute coronary syndromes care. *Circ Cardiovasc Qual Outcomes*. 2011;4:211-19. PMID: 21304094.
164. Ohman EM, **Roe MT**. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. *Thromb Haemost*. 2011;105:763-65. PMID:21394382.
165. Britton KA, Aggarwal V, Chen AY, Alexander KP, Amsterdam E, Fraulo E, Muntner P, Thomas L, McGuire DK, Wiviott SD, **Roe MT**, Schubart UK, Fox CS. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. *Am Heart J*. 2011;161:657-63. PMID: 21473963.
166. Alexander KP, Wang TY, Li S, Lytle BL, Slattery LE, Calhoun S, Poteat J, **Roe MT**, Rumsfeld JS, Cannon CP, Peterson ED. Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care. *Circ Cardiovasc Qual Outcomes* 2011;4:129-35. PMID: 21245461.
167. Wang TY, Peterson ED, Ou FS, Nallamothu BK, Rumsfeld JS, **Roe MT**. Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: A report from the national cardiovascular data registry. *Am Heart J*. 2011;61:76-83. PMID: 21167337.

168. Burjonrappa SC, Varosy PD, Rao SV, Ou FS, **Roe MT**, Peterson E, Singh M, Shunk KA. Survival of Patients Undergoing Rescue Percutaneous Coronary Intervention. *J Am Coll Cardiol Cardiovas Interv.* 2011;4:42-50. PMID: 21251628.
169. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, **Roe MT**. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. *Am Heart J.* 2011;161:113-22. PMID: 21167342.
170. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, **Roe MT**, Alexander KP. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. *Am J Cardiol.* 2011;107:1136-43. PMID: 21324428.
171. Kontos MC, Lemos JA, Ou FS, Wiviott SD, Foody JM, Newby LK, Chen A, **Roe MT**. Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION-GWTG) Registry. *Am Heart J.* 2010; 160:819-25. PMID: 21095267.
172. Wang TY, Peterson ED, Ou FS, Nallamothu BK, Rumsfeld JS, **Roe MT**. Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: A report from the national cardiovascular data registry. *Am Heart J.* 2011;161:76-83. PMID: 21167337.
173. Melloni C, Shah BR, Ou FS, **Roe MT**, Smith SC, Pollack CV, Ohman M, Gibler BW, Peterson ED, and Alexander KP. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications Applied and Sustained over Time (MAINTAIN) registry. *Am Heart J.* 2010;160:1121-29. PMID: 21146667.
174. Mudrick DW, Chen AY, **Roe MT**, Newby KL, Gibler BW, Ohman ME, Peterson ED, Alexander KP. Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. *Am Heart J.* 2010;160:1072-78. PMID: 21146660.
- a.
175. Peterson ED, **Roe MT**, Chen AY, Fonarow GC, Lytle BL, Cannon CP, Rumsfeld JS. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. *Heart.* 2010;96:1798-802. PMID: 20736202.
176. Brilakis ES, Wang TY, Rao SV, Banerjee S, Goldman S, Shunk K, Kar B, Holmes DR Jr, Dai D, Chin CT, Harding TM, **Roe MT**. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. *J Am Coll Cardiol Cardiovas Interv.* 2010;3:1068-73. PMID: 20965466.
177. Mehta RH, Chen AY, Ohman EM, Gibler WB, Peterson ED, **Roe MT**. Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non-ST-segment elevation myocardial infarction. *Am Heart J.* 2010;160:405-11. PMID: 20826246.

178. Ting HH, Chen AY, **Roe MT**, Chan PS, Spertus JA, Nallamothu BK, Sullivan MD, DeLong ER, Bradley EH, Krumholz HM, and Peterson ED. Delay from symptom onset to hospital presentation for patients with non-ST-segment elevation myocardial infarction. *Arch Intern Med.* 2010;170:1834-41. PMID: 21059977.
179. Russell SD, Blackwell KL, Lawrence J, Pippen JE, Jr, **Roe MT**, Wood F, Paton V, Holmgren E, Mahaffey KW. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the north central cancer treatment group N9831 clinical trials. *J Clin Oncol.* 2010;28:3416-21. PMID: 20530275.
180. Ohman EM, **Roe MT**, Armstrong PW, Fox KA, Prabhakaran D, White HD. Public sensationalism and clinical trials: How to address the challenges of science? *Am J Med.* 2010;123:481-83. PMID: 20400058.
181. Gharacholou SM, Alexander KP, Chen AY, Wang TY, Melloni C, Gibler WB, Pollack CV Jr, Ohman EM, Peterson ED, **Roe MT**. Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. *Am Heart J.* 2010;159:757-63. PMID: 20435183.
182. Lopes RD, Peterson ED, Chen AY, **Roe MT**, Wang TY, Ohman EM, Magid DJ, Ho PM, , Wiviott SD, Scirica BM, Alexander KP. Antithrombotic Strategy in Non-ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention Insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. *J Am Coll Cardiol Cardiovas Interv.* 2010;3:669-77. PMID: 20630461.
183. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, **Roe MT**, Kochman J, Huber JK, Zeymer U, Madan M, et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) *Am Heart J.* 2010;160:65-72. PMID: 20598974.
184. **Roe MT**, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, Chen AY, Klein LW, Masoudi FA, McKay C, Hewitt K, Brindis RG, Peterson ED, Rumsfeld JS,. Treatments, Trends, and Outcomes of Acute Myocardial Infarction and Percutaneous Coronary Intervention. *J Am Coll Cardiol.* 2010;56:254-63. PMID: 20633817.
185. Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, Shaw RE, **Roe MT**, Ho KL, Klein LW, Krone RJ, Weintraub WS, Brindis RG, Rumsfeld JS, Spertus JA. Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention Results from 588,398 Procedures in the National Cardiovascular Data Registry. *J Am Coll Cardiol.* 2010;55:1923-32. PMID: 20430263.
186. Parikh SV, Lemos JA, Jessen ME, Brilakis ES, Ohman EM, Chen AY, Wang TY, Peterson ED, **Roe MT**, Holper EM. Timing of In-Hospital Coronary Artery Bypass Graft Surgery for Non-ST-Segment Elevation Myocardial Infarction Patients - Results From the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). *J Am Coll Cardiol Cardiovas Interv.* 2010;3:419-27. PMID: 20398870.
187. Tavis D, Shoaibi A, Chen AY, Uchida T, **Roe MT**, Chen J. Gender differences in the treatment of non-ST-segment elevation myocardial infarction. *Clin Cardiol.* 2010;33:99-103. PMID: 20186991.

188. Glickman SW, Cairns CB, Chen AY, Peterson ED, **Roe MT**. Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. *Am Heart J*. 2010;159:998-1004. PMID: 20569712.
189. Shah BR, Peterson ED, Chen AY, Mahaffey KW, DeLong ER, Ohman EM, Pollack CV Jr, Gibler WB, **Roe MT**. Influence of clinical trial participation on subsequent antithrombin use. *Clin Cardiol*. 2010;33:49-55. PMID: 20127904.
190. Chin CT, **Roe MT**, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. *Am Heart J*. 2010;160:16-22. PMID: 20598967.
191. Glickman SW, Boulding W, Manary M, Staelin R, **Roe MT**, Wolosin RJ, Ohman EM, Peterson ED, Schulman KA. Patient Satisfaction and Its Relationship with Clinical Quality and Inpatient Mortality in Acute Myocardial Infarction. *Circ Cardiovasc Qual Outcomes*. 2010;3:188-95. PMID: 20179265.
192. Bangalore S, Messerli FH, Ou FS, Tamis-Holland J, Palazzo A, **Roe MT**, Hong MK, Peterson ED. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. *Eur Heart J*. 2010;31:552-60. PMID: 19793769
193. Fox CS, Muntner P, Chen AY, Alexander KP, **Roe MT**, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non-ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease. *Circulation*. 2010;121:357-65. PMID: 20065168.
194. Cudnik MT, Peacock WF, Diercks DB, **Roe MT**, Chen AY. Prehospital Electrocardiograms (ECGs) Do Not Improve the Process of Emergency Department Care in Hospitals with Higher Usage of ECGs in Non-ST-Segment Elevation Myocardial Infarction Patients. *Clin Cardiol*. 2009;32:668-74. PMID: 20027666.
195. Singh M, Peterson ED, **Roe MT**, Ou FS, Spertus JA, Rumsfeld JS, Anderson HV, Klein LW, Ho KK, Holmes DR. Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. *Circ Cardiovasc Interv*. 2009;2:20-26. PMID: 20031689.
196. Atwater BD, Thompson VP, Vest RN III, Shaw LK, Mazzei WR Jr, Al-Khatib SM, Hranitzky PM, Bahnson TD, Velazquez EJ, Califf RM, Lee KL, **Roe MT**. Usefulness of the Duke Sudden Cardiac Death Risk Score for Predicting Sudden Cardiac Death in Patients With Angiographic (>75% Narrowing) Coronary Artery Disease. *Am J Cardiol*. 2009;104:1624-30. PMID: 19962465.
197. Bangalore S, Messerli FH, Ou FS, Tamis-Holland J, Palazzo A, **Roe MT**, Hong MK, Peterson ED, CRUSADE Investigators. Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: Results from 139,194 patients in the Can Rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative. *Am Heart J*. 2009;157:525-31. PMID: 19249424.

198. Tsai TT, Maddox M, **Roe MT**, Dai D, Alexander KP, Ho PM, Messenger JC, Nallamothu BK, Peterson ED, Rumsfeld JS, National Cardiovascular Data Registry. Contraindicated Medication Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention. *JAMA*. 2009;30:2458-66. PMID: 19996401.
199. Pollack CV Jr, Hollander JE, Chen AY, Peterson ED, Bangalore S, Peacock FW, Cannon CP, Canto JG, Gibler BW, Ohman ME, **Roe MT**. Non-ST-Elevation Myocardial Infarction Patients Who Present During Off Hours Have Higher Risk Profiles and are Treated Less Aggressively, but Their Outcomes are Not Worse. *Crit Pathways Cardiol*. 2009;8:29-33. PMID: 19258835.
200. Amsterdam EA, Peterson ED, Ou FS, Newby LK, Pollack CV Jr, Gibler WB, Ohman EM, **Roe MT**. Comparative Trends in Guidelines Adherence Among Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Treated with Invasive Versus Conservative Management Strategies: Results from the CRUSADE Quality Improvement Initiative. *Am Heart J*. 2009;158:748-54. PMID: 19853692.
201. Berger JS, **Roe MT**, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y1ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid Reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) pilot trial. *Am J Heart*. 2009;158:998-1004. PMID: 19958867.
202. Allen-LaPointe NM, Chen AY, **Roe MT**, Cohen DJ, Diercks DB, Hoekstra JW, Fesmire FM, Gibler WB, Ohman EM, Peterson ED. Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome. *Am J Cardiol*. 2009;104:1324-29. PMID: 19892045.
203. Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, **Roe MT**, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW. Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (From the International Trial SYNERGY). *Am J Cardiol*. 2009;104:1330-35. PMID: 19892046.
204. Gehrie ER, Reynolds HR, Chen AY, Neelon BH, **Roe MT**, Gibler WB, Ohman EM, Newby LK, Peterson ED, Hochman JS. Characterization and Outcomes of Women and Men With Non-ST-Segment Elevation Myocardial Infarction and Nonobstructive Coronary Artery Disease: Results From The Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes With Early Implementation of The ACC/AHA Guidelines (CRUSADE) Quality Improvement Initiative. *Am Heart J*. 2009;158:688-94. PMID: 19781432.
205. Ali RC, Melloni C, Ou FS, Schmader K, Ohman EM, **Roe MT**, Peterson ED, Alexander KP. Age and persistent use of cardiovascular medication after acute coronary syndrome: Results from medication applied and sustained over time. *J Am Geriatr Soc*. 2009;57:1990-96. PMID: 19754499.
206. Takakuwa KM, Ou FS, Peterson ED, Pollack CV Jr, Peacock WF, Hoekstra JW, Ohman EM, Gibler WB, Blomkalns AL, **Roe MT**. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: Results from CRUSADE. *Clin Cardiol*. 2009;32:498-505. PMID: 19743496.
207. Fermann GJ, Raja AS, Peterson ED, **Roe MT**, Hoekstra JW, Milford-Beland S, Diercks DB, Pollack CV Jr, Peacock WF, Summers R, Ohman EM, Gibler WB. Early treatment for non-ST-segment elevation acute

coronary syndrome is associated with appropriate discharge care. *Clin Cardiol.* 2009;32:519-25. PMID: 19743495.

208. Peterson ED, **Roe MT**, Rumsfeld JS, Shaw RE, Brindis RG, Fonarow GC, Cannon CP. A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network): A National Effort to Promote Timely Clinical Feedback and Support Continuous Quality Improvement for Acute Myocardial Infarction. *Circ Cardiovasc Qual Outcomes.* 2009;2:491-99. PMID: 20031882.
209. **Roe MT**, Chen AY, Cannon CP, Rao SV, Rumsfeld JS, Magid DJ, Brindis RG, Klein LW, Gibler WB, Ohman EM, Peterson ED. Temporal changes in the use of drug-eluting stents for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: Results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Averse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Coronary Treatment and Intervention Outcomes Network Get With The Guidelines (ACTION GWTG) Registries. *Circ Cardiovasc Qual Outcomes.* 2009;2:414-20. PMID: 20031871.
210. Wang TY, Newby LK, Chen AY, Mulgund J, **Roe MT**, Sonel AF, Bhatt DL, DeLong ER, Ohman EM, Gibler WB, Peterson ED. Hypercholesterolemia paradox in Relation to Mortality in Acute Coronary Syndrome. *Clin Cardiol.* 2009;9:22-28. PMID: 19645040.
211. Cohen MG, Filby SJ, **Roe MT**, Chen AY, Menon V, Stouffer GA, Gibler WB, Smith SC, Pollack CV, Peterson ED, Ohman EM. The Paradoxical Use of Cardiac Catheterization in Patients with Non-ST-Elevation Acute Coronary Syndromes: Lessons From The Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) Quality Improvement Initiative. *Am Heart J.* 2009;158:263-70. PMID: 19619704.
212. Aggarwal A, Dai D, Rumsfeld JS, Klein LW, **Roe MT**. Incidence and Predictors of Stroke Associated With Percutaneous Coronary Intervention. *Am J Cardiol.* 2009;104:349-53. PMID: 19616666.
213. Cavender MA, Milford-Beland S, **Roe MT**, Peterson ED, Weintraub WS, Rao SV. Prevalence, Predictors, and In-Hospital Outcomes of Non-Infarct Artery Intervention during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (from the National Cardiovascular Data Registry). *Am J Cardiol.* 2009;104:507-13. PMID: 19660603.
214. Melloni C, Alexander KP, Ou FS, Allen-LaPointe NM, **Roe MT**, Newby LK, Baloch K, Ho PM, Rumsfeld JS, Peterson ED. Predictors of Early Discontinuation of Evidence-Based Medicine after Acute Coronary Syndrome. *Am J Cardiol.* 2009;102:175-81. PMID: 19576342.
215. Chandra A, Glickman SW, Ou FS, Peacock WF, McCord JK, Cairns CB, Peterson ED, Ohman EM, Gibler WB, **Roe MT**. An Analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association Non-ST-Segment Elevation Myocardial Infarction Guideline Adherence. *Ann Emerg Med.* 2009;54:17-25. PMID: 19282062.
216. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, Ou FS, **Roe MT**, Peterson ED, Marso SP, and on Behalf of the National Cardiovascular Data Registry. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm from the National Cardiovascular Data Registry. *Circ Cardiovasc Intervent.* 2009;2:222-29. PMID: 20031719.
217. Chan MY, Sun JL, Newby LK, Shaw LK, Lin M, Peterson ED, Califf RM, Kong DF, **Roe MT**. Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial Infarction. *Circulation.* 2009;119:3110-17. PMID: 19506116.

218. Harrington RA, Califf RM, Hodgson PK, Peterson ED, **Roe MT**, Mark DB. Careers for Clinician Investigators. *Circulation*. 2009;19:2945-50. PMID: 19506126.
219. Spinler SA, Ou FS, **Roe MT**, Gibler WB, Ohman EM, Pollack CV, Alexander KP, Peterson ED. Weight-Based Dosing of Enoxaparin in Obese Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: Results from the CRUSADE Initiative. *Pharmacotherapy*. 2009;29:631-38. PMID: 19476416.
220. Halim SA, Mulgund J, Chen AY, **Roe MT**, Peterson ED, Gibler WB, Ohman EM, Newby LK. Use of Guidelines-Recommended Management and Outcomes among Women and Men with Low-Level Troponin Elevation: Insights from CRUSADE. *Circ Cardiovasc Qual Outcomes*. 2009;2:199-206. PMID: 20031838.
221. Wang TY, Ou FS, **Roe MT**, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Incidence and Prognostic Significance of Thrombocytopenia Developed During Acute Coronary Syndrome in Contemporary Clinical Practice. *Circulation*. 2009;119:2454-62. PMID: 19398666.
222. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, **Roe MT**. Prior Polyvascular Disease: Risk Factor for Adverse Ischemic Outcomes in Acute Coronary Syndromes. *Eur Heart J*. 2009;30:1195-1202. PMID: 19339264.
223. Wang TY, Zhang M, Fu Y, Armstrong PW, Newby LK, Gibson CM, Moliterno DJ, Van de Werf F, White HD, Harrington RA, **Roe MT**. Incidence, distribution and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. *Am Heart J*. 2009;15:716-23. PMID: 19332201.
224. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, **Roe MT**, Pollack CV Jr, Peterson ED, Alexander KP. Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation*. 2009;119:1873-82. PMID: 19332461.
225. Patel UD, Ou FS, Ohman EM, Gibler WB, Pollack CV Jr, Peterson ED, **Roe MT**. Hospital Performance and Differences by Kidney Function in the Use of Recommended Therapies After Non-ST-Elevation Acute Coronary Syndromes. *Am J Kidney Dis*. 2009;53:426-37. PMID: 19100672.
226. Cardarelli F, Bellasi A, Ou FS, Shaw LJ, Veledar E, **Roe MT**, Morris DC, Peterson ED, Klein LW, Raggi P. Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of Cardiology National Cardiovascular Data Registry). *Am J Cardiol*. 2009;103:766-71. PMID:19268729.
227. Diercks DB, Kontos MC, Chen AY, Pollack CV Jr., Wiviott SD, Rumsfeld JS, Magid DJ, Gibler WB, Cannon CP, Peterson ED, **Roe MT**. Utilization and Impact of Pre-Hospital Electrocardiograms for Patients with Acute ST-Segment Elevation Myocardial Infarction: Data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. *J Am Coll Cardiol*. 2009;53:161-66. PMID: 19130984.
228. Akhter N, Milford-Beland S, **Roe MT**, Piana RN, Kao J, Shroff A. Gender Differences among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in the American College of

Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J.* 2009;157:141-48. PMID: 19081410.

229. Mehta RH, Ou FS, Peterson ED, Shaw RE, Hillegrass WB Jr, Rumsfeld JS, **Roe MT**. Clinical Significance of Post-Procedural TIMI Flow in Patients With Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention. *J Am Coll Cardiol Cardiovas Interv.* 2009;2:56-64. PMID: 19463399.
230. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, **Roe MT**, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR, Becker RC; 2008 Platelet Colloquim Participants. G-protein-coupled receptors as signaling targets for antiplatelet therapy. *Arterioscler Thromb Vasc Biol.* 2009;29:449-57. PMID: 19023091.
231. Alexander D, Mann N, Ou F, Peterson ED, Ohman EM, Gibler WB, **Roe MT**. Patterns of Upstream Antiplatelet Therapy Use Before Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction: Results from CRUSADE National Quality Improvement Initiative. *Am J Cardiol.* 2008;102:1335-40. PMID: 18993151.
232. Dixon WC IV, Wang TY, Dai D, Shunk KA, Peterson ED, **Roe MT**. Anatomic distribution of the culprit lesion in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Findings from the National Cardiovascular Data Registry. *J Am Coll Cardiol.* 2008;52:1347-48. PMID: 18929247.
233. Wang TY, Chen AY, Alexander KP, Ohman EM, Gibler WB, Peterson ED, **Roe MT**. Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. *Am J Med.* 2008;121:805-10. PMID: 18724971.
234. Sayah AJ, **Roe MT**. The role of fibrinolytics in the prehospital treatment of ST-elevation myocardial infarction (STEMI). *J Emerg Med.* 2008;34:405-16. PMID: 18164167.
235. Peterson ED, Bynum DZ, **Roe MT**. Association of evidence-based care processes and outcomes among patients with acute coronary syndromes: Performance matters. *J Cardiovasc Nurs.* 2008;23:50-55. PMID: 18158508.
236. Lytle BL, Fraulo ES, Mulgund J, Miller VA, **Roe MT**, Smith SC Jr, Gibler WB, Ohman EM, Peterson ED. What aspects of hospital culture influence quality? *Crit Pathw Cardiol.* 2007;6:145-49. PMID: 18091403.
237. Rao SV, Ou FS, Wang TY, **Roe MT**, Brindis R, Rumsfeld JR, Peterson ED. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: A report from the National Cardiovascular Data Registry. *J Am Coll Cardiol Cardiovas Interv* 2008;1:379-86. PMID: 19463333.
238. Alexander D, Ou FS, **Roe MT**, Pollack CV, Ohman EM, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DL. Use of and in-hospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction. *Am Heart J.* 2008; 156:606-12. PMID: 18760147.
239. Madala MC, Franklin BA, Chen AY, Berman AD, **Roe MT**, Peterson ED, Ohman EM, Smith SC Jr, Gibler WB, McCullough PA. Obesity and age of first non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol.* 2008;52:979-85. PMID: 18786477.

240. **Roe MT**, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, Boden WE, Ohman EM, Smith SC Jr, Peterson ED. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. *Eur Heart J.* 2008;29:2480-88. PMID: 18716006.
241. Dunlay SM, Alexander KP, Melloni C, Kraschnewski JL, Liang L, Gibler WB, **Roe MT**, Ohman EM, Peterson ED. Medical Records and Quality of Care in Acute Coronary Syndromes. *Arch Int Med.* 2008; 168:1692-98. PMID: 18695085.
242. **Roe MT**, Kikano G, Mioller CD, Hoekstra JW. Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): Importance of platelet and coagulation inhibition. *Postgrad Med.* 2008;120:67-78. PMID: 18654071.
243. Peterson ED, Bynum DZ, **Roe MT**. Lessons learned from the CRUSADE National Quality Improvement initiative. *Curr Cardiol Rep.* 2008;10:285-90. PMID: 18611362.
244. **Roe MT**, Chen AY, Delong ER, Boden WE, Calvin JE Jr, Cairns CB, Smith SC Jr, Pollack CV Jr, Brindis RG, Califf RM, Gibler WB, Ohman EM, Peterson ED. Patterns of transfer for patients with non-ST-segment elevation acute coronary syndromes from community to tertiary care hospitals. *Am Heart J.* 2008; 156:185-92. PMID: 18585515.
245. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, Allen LaPointe NM, Ohman EM, **Roe MT**, Boden WE, Harrington RA, Peterson ED. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. *Am Heart J.* 2008;155:1047-53. PMID: 18513518.
246. Melloni C, Alexander KP, Chen AY, Newby LK, **Roe MT**, Allen LaPointe NM, Pollack CV Jr, Gibler WB, Ohman EM, Peterson ED. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. *Am Heart J.* 2008;156:209-15. PMID: 18657648.
247. Aggarwal A, Dai D, Rumsfeld JR, Klein LW, **Roe MT**. Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention. *Am J Cardiol.* 2008;101:1413-17. PubMed PMID: 18471451. PMID: 18471451.
248. Wang TY, Peterson ED, Dai D, Anderson HV, Rao SV, Brindis RG, **Roe MT**. Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: A report from the National Cardiovascular Data Registry (NCDR). *J Am Coll Cardiol.* 2008;51:2068-74. PMID: 18498965.
249. Chan MY, Mahaffey KW, Sun LJ, Pieper KS, White HD, Aylward PE, Ferguson JJ, Califf RM, **Roe MT**. Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary artery disease. *J Am Coll Cardiol Cardiovas Interv.* 2008;1:369-78. PMID: 19463332.
250. Brener SJ, Milford-Beland S, **Roe MT**, Bhatt DL, Weintraub WS, Brindis RG. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: An American College of Cardiology National Cardiovascular Database Registry report. *Am Heart J.* 2008;155:140-46. PMID: 18082505.
251. Wang TY, Chen AY, Peterson ED, Becker RC, Gibler WB, Ohman EM, **Roe MT**. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-elevation acute coronary syndromes. *Eur Heart J.* 2008;29:1103-09. PPMID: 18353757.

252. Ting HH, **Roe MT**, Gersh BJ, Spertus JA, Rumsfeld FS, Ou FS, Kao J, Hall Long K, Holmes DR Jr, Peterson ED. Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction. *Am J Cardiol.* 2008;101:286–92. PMID: 18237586.
253. The DELTA MI Investigators (**Roe MT** - corresponding and lead author of writing group). Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction - Direct inhibition of δ -protein kinase C enzyme to limit total infarct size in acute myocardial infarction. *Circulation.* 2008;117:886-96. PMID: 18250271.
254. Melloni C, Alexander KP, Milford-Beland S, Newby LK, Szezech LA, Pollack CV Jr, Kirk JD, Christenson RH, Harrington RA, Gibler WB, Ohman EM, Peterson ED, **Roe MT**. Prognostic value of troponins in patients with non-ST-elevation acute coronary syndromes and chronic kidney disease. *Clin Cardiol.* 2008; 31:125-29. PMID: 18383049.
255. Wang TY, Robinson LA, Ou F, **Roe MT**, Ohman EM, Gibler WB, Smith SC Jr, Peterson ED, Becker RC. Discharge antithrombotic strategies among patients with acute coronary syndromes previously on warfarin anticoagulation: Physician practice in the CRUSADE registry. *Am Heart J.* 2008;155:361-68. PMID: 18215609.
256. Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, Harrington RA, Gibler WB, Ohman EM, Spinler SA, **Roe MT**, Alexander KP. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. *J Am Coll Cardiol.* 2008;51:991-96. PMID: 18325437.
257. Majumdar SR, **Roe MT**, Peterson ED, Chen AY, Gibler WB, Armstrong PW. Better outcomes for patients treated at hospitals that participate in clinical trials. *Arch Intern Med.* 2008;168:657-62. PMID: 18362259. PubMed PMID: 18362259.
258. Chan MY, Becker RC, Harrington RA, Peterson ED, Armstrong PW, White H, Fox MB, Keith AA, Ohman EM, **Roe MT**. Noninvasive, medical management for non–ST-elevation acute coronary syndromes. *Am Heart J.* 2008;155:397-407. PMID: 18294472.
259. Diercks DB, **Roe MT**, Chen AY, Peacock WF, Kirk JD, Pollack CV Jr, Gibler WB, Smith SC Jr, Ohman EM, Peterson ED. Prolonged emergency department stays are associated with worse adherence to the ACC/AHA guidelines for management of non–ST-segment elevation myocardial infarction and increased adverse events. *Ann Emerg Med.* 2007;50:489-96. PMID: 17583379.
260. Glickman SW, Boulding W, Staelin R, Mulgund J, **Roe MT**, Lytle BL, Rumsfeld JS, Gibler WB, Ohman EM, Schulman KA, Peterson ED. A framework for quality improvement: An analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. *Am Heart J.* 2007;154:1206-20. PMID: 18035096.
261. Zia MI, Goodman SG, Peterson ED, Mulgand J, Chen AY, Langer A, Tan M, Ohman EM, Gibler WB, Pollack CV Jr, **Roe MT**. Paradoxical use of invasive cardiac procedures for patients with non-ST-segment elevation myocardial infarction: An international perspective from the CRUSADE initiative and the Canadian ACS registries I and II. *Can J Cardiol.* 2007;23:1073-79. PMID: 17985010.
262. Blomkalns AL, **Roe MT**, Peterson ED, Ohman EM, Fraulo ES, Gibler WB. Guideline implementation research: Exploring the gap between evidence and practice in the CRUSADE Quality Improvement Initiative. *Acad Emerg Med.* 2007;14:949-54. PMID: 17967956.

263. Atwater BD, Milford-Beland S, Newby LK, Hernandez AF, Peacock WF, Gibler WB, Christenson RH, Ohman EM, Peterson ED, **Roe MT**. Patterns and implications of B-type natriuretic peptide measurement in patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol*. 2007;100:1727-33. PMID: 18082516.
264. Wang TY, Chen AY, **Roe MT**, Alexander KP, Newby LK, Smith SC, Bangalore S, Gibler WB, Ohman EM, Peterson ED. Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of asian versus non-asian white americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative. *Am J Cardiol*. 2007;100:391-96. PMID: 17659915.
265. Allen LaPointe NM, Chen AY, Alexander KP, **Roe MT**, Pollack CV Jr, Lytle BL, Ohman EM, Gibler WB, Peterson ED. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. *Arch Intern Med*. 2007;167:1539-44. PMID: 17646609.
266. Steinhubl S, **Roe MT**. Optimizing platelet P2Y12 inhibition for patients undergoing PCI. *Cardiovasc Drug Rev*. 2007;25:188-203. PMID: 17614940.
267. Nallamothu BK, Krumholz HM, Ko DT, LaBresh KA, Rathore S, **Roe MT**, Schwamm L. Development of systems of care for ST-elevation myocardial infarction patient's gaps, barriers, and implications. *Circulation*. 2007;115:e68-e72. PMID: 17538036.
268. Miller CD, **Roe MT**, Mulgund J, Hoekstra JW, Santos R, Pollack CV Jr, Ohman EM, Gibler WB, Peterson ED. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE quality improvement initiative. *Am J Med*. 2007;120:685-92. PMID: 17679127.
269. Tickoo S, **Roe MT**, Peterson ED, Milford-Beland S, Ohman EM, Gibler WB, Pollack CV Jr, Cannon CP. Patterns of Aspirin Dosing in Non-ST-Elevation Acute Coronary Syndromes in the CRUSADE Quality Improvement Initiative. *Am J Cardiol*. 2007;99:1496-99. PMID: 17531568.
270. Shah BR, Glickman SW, Liang L, Gibler WB, Ohman EM, Pollack CV Jr, **Roe MT**, Peterson ED. The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results from CRUSADE. *J Am Coll Cardiol*. 2007;50:1462-68. PMID: 17919566.
271. Glickman SW, Ou FS, DeLong ER, **Roe MT**, Lytle BL, Mulgund J, Rumsfeld JS, Gibler WB, Ohman EM, Schulman KA, Peterson ED. Pay for Performance, Quality of Care, and Outcomes in Acute Myocardial Infarction. *JAMA*. 2007;297:2373-80. PMID: 17551130.
272. **Roe MT**, Chen AY, Mehta RH, Li Y, Brindis RG, Smith SC Jr, Rumsfeld JS, Gibler WB, Ohman EM, Peterson ED. Influence of Inpatient Service Specialty on Care Processes and Outcomes for Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. *Circulation*. 2007;116:1153-61. PMID: 17709638.
273. Bennett KM, Hernandez AF, Mulgund J, Newby LK, Rumsfeld JS, Hochman JS, Hoekstra JW, Ohman EM, Gibler WB, **Roe MT**, Peterson ED. Heart Failure With Preserved Left Ventricular Systolic Function Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. *Am J Cardiol*. 2007; 99:1351-56. PMID: 17493458.
274. Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV Jr, Ohman EM, Gibler WB, **Roe MT**. Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing

Percutaneous Coronary Intervention: Results from CRUSADE. *Am J Cardiol.* 2007;99:1389-93. PMID: 17493466.

275. Gogo PB Jr, Dauerman HL, Mulgund J, Ohman EM, Patel MR, Cohen DJ, Saucedo JF, Harrington RA, Gibler WB, Smith SC Jr, Peterson ED, **Roe MT**. CRUSADE Investigators. Changes in Patterns of Coronary Revascularization Strategies for Patients with Acute Coronary Syndromes (from the CRUSADE Quality Improvement Initiative). *Am J Cardiol.* 2007;99:1222-26. PMID: 17478146.
276. Skolnick AH, Alexander KP, Chen AY, **Roe MT**, Pollack CV Jr, Ohman EM, Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, Management, and Outcomes of 5,557 Patients Age > 90 Years with Acute Coronary Syndromes Results from the CRUSADE Initiative. *J Am Coll Cardiol.* 2007;49:1790-99. PMID: 17466230.
277. Mahaffey KW, **Roe MT**, Kilaru R, Alexander JH, Van de Werf F, Califf RM, Simoons ML, Topol EJ, Harrington RA. Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. *Eur Heart J.* 2007;28:425-32. PMID: 17267458.
278. Mehta RH, Milford-Beland S, Peterson ED, Bhatt DL, Farkouh ME, Brogan GX, Gibler WB, Ohman EM, **Roe MT**. Characterizing Young Patients With Diabetes and Non-ST-Segment Elevation Acute Coronary Syndromes. *Diabetes Care.* 2007;30:731-33. PMID: 17327352.
279. **Roe MT**, Halabi AR, Mehta RH, Chen AY, Kristin Newby L, Harrington RA, Smith SC Jr, Ohman EM, Gibler WB, Peterson ED. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. *Am Heart J* 2007;153:507-14. PMID: 17383286.
280. Patel MR, Chen AY, **Roe MT**, Ohman EM, Newby LK, Harrington RA, Smith SC Jr, Gibler WB, Calvin JE, Peterson ED. A Comparison of Acute Coronary Syndrome Care at Academic and Non-Academic Hospitals—Results from the CRUSADE Initiative. *Am J Med.* 2007;120:40-46. PMID: 17208078.
281. Singh KP, **Roe MT**. ASSENT-4 PCI: Should facilitated percutaneous coronary intervention be used in clinical practice? *Nat Clin Pract Cardiovasc Med.* 2006;8:420-26. PMID: 16874353.
282. Tricoci P, Mulgund J, Harrington RA, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger P, Cannon CP, Cohen DJ, Hochman JS, Gibler WB, Ohman EM, Peterson ED, Smith SC Jr, **Roe MT**. Temporal Trends in The Use of Early Cardiac Catheterization in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes (Results from CRUSADE). *Am J Cardiol.* 2006;98:1172-76. PMID: 17056321.
283. Calvin JE, **Roe MT**, Chen AY, Mehta RH, Brogan GX, DeLong ER, Fintel DJ, Gibler WB, Ohman EM, Smith SC, Peterson ED. Insurance Coverage and Care of Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. *Ann Intern Med.* 2006;145:739-48. PMID: 17116918.
284. Peterson ED, **Roe MT**. Continued improvements in quality improvement research. *Am Heart J.* 2006; 152:1005-20. PMID: 17161043.
285. Mehta RH, Chen AY, Pollack CV Jr, **Roe MT**, Zalenski RJ, Clements EA, Gibler WB, Ohman EM, Harrington RA, Peterson ED. Challenges in Predicting the Need for Coronary Artery Bypass Grafting at Presentation in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. *Am J Cardiol.* 2006; 98:624-27. PMID: 16923449.

286. Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV Jr, Brindis RG, Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, Harrington RA, **Roe MT**. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. *Am Heart J*. 2006;152:641-47. PMID: 16996828.
287. Mehta RH, **Roe MT**, Chen AY, Lytle BL, Pollack CV, Brindis RG, Smith SC, Harrington RA, Fintel D, Fraulo ES, Califf RM, Gibler WB, Ohman EM, Peterson ED. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: Insights from the CRUSADE initiative. *Arch Int Med*. 2006;166:2027-34. PMID: 17030838.
288. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, **Roe MT**, Gibler WB, Ohman, EM, Peterson ED. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE (Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) initiative. *Circulation*. 2006;114:1380-87. .PMID: 16982940.
289. Mehta RH, Newby LK, Patel Y, Hoekstra JW, Miller CD, Chen AY, Lytle BL, Diercks DB, Summers RL, Brogan GX, Peacock WF, Pollack CV, **Roe MT**, Peterson ED, Ohman EM, Gibler WB, for the CRUSADE Investigators. The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes. *Am Heart J*. 2006;152:648-60. .PMID: 16996829.
290. Rokos IC, Larson DM, Henry TD, Koenig WJ, Eckstein M, French WJ, Granger CB, **Roe MT**. Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks. *Am Heart J*. 2006;152:771-77. PMID: 16996830.
291. Menon V, Rumsfeld JS, **Roe MT**, Cohen MG, Peterson ED, Brindis RG, Chen AY, Pollack CV Jr, Smith SC Jr, Gibler WB, Ohman EM. Regional Outcomes Following Admission for High-Risk Non-ST Segment Elevation Acute Coronary Syndromes. *Am J Med*. 2006;119:584-90. PMID: 16828630.
292. Mehta RH, **Roe MT**, Mulgund J, Ohman EM, Cannon CP, Gibler WB, Pollack CV Jr, Smith SC Jr, Ferguson TB, Peterson ED. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. *J Am Coll Cardiol*. 2006;48:281-86. . PMID: 16843176.
293. Diercks DB, **Roe MT**, Mulgund J, Pollack CV Jr, Kirk JD, Gibler WB, Ohman EM, Smith SC Jr, Boden WE, Peterson ED. The Obesity Paradox in Non-ST-segment Elevation Acute Coronary Syndromes: Results from the CRUSADE Quality Improvement Initiative. *Am Heart J*. 2006;152:140-48. . PMID: 16824844.
294. Cohen MG, **Roe MT**, Mulgund J, Peterson ED, Sonel AF, Menon V, Smith SC Jr, Saucedo JF, Lytle BL, Pollack CV Jr, Garza L, Gibler WB, Ohman EM. Clinical Characteristics, Process of Care, and Outcomes of Hispanic Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndromes: Results from CRUSADE. *Am Heart J*. 2006;152:110-17. PubMed PMID: 16824839.
295. Han JH, Chandra A, Mulgund J, **Roe MT**, Peterson ED, Szezech LA, Patel U, Ohman EM, Lindsell CJ, Gibler WB. Moderate to Severe Chronic Kidney Disease and its Relationship to Care and Outcomes of Patients with NSTEMI ACS: Results from the CRUSADE Initiative. *Am J Med*. 2006;119:248-54. PMID:16490471.
296. Singh KP, **Roe MT**, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, Ohman EM, Pollack CV Jr. Low-molecular-weight heparin compared with unfractionated heparin for

patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors. *J Thromb Thrombol.* 2006;21:211-20. PMID: 16683212.

297. **Roe MT**, Peterson ED, Newby LK, Chen AY, Pollack CV Jr., Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Braunwald E, Gibler WB, Ohman EM. The influence of risk status on guidelines adherence for patients with non-ST-segment elevation acute coronary syndromes. *Am Heart J.* 2006;151:1205-13. PMID: 16781220.
298. **Roe MT**, Chen AY, Riba AL, Goswami RG, Peacock WF, Pollack CV Jr., Collins SP, Gibler WB, Ohman EM, Peterson ED. Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol.* 2006;97:1707-12. PMID: 16765118.
299. Tricoci P, **Roe MT**, Mulgund J, Newby LK, Smith SC Jr, Pollack CV Jr, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA. Utilization of clopidogrel at discharge in patients with non-ST-segment elevation acute coronary syndromes. *Arch Intern Med.* 2006;166:806-11. PMID: 16606819.
300. Tricoci P, Peterson ED, **Roe MT**. Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction. *Am J Cardiol.* 2006 18;98:30Q-35Q. PMID: 17116918.
301. Peterson ED, **Roe MT**, Mulgund J, DeLong ER, Lytle BL, Brindis RG, Smith SC Jr, Pollack CV Jr, Newby LK, Harrington RA, Gibler WB, Ohman EM. Association between hospital process performance and outcomes among patients with acute coronary syndromes. *JAMA.* 2006; 295:1912-20. PMID: 16639050.
302. Tricoci P, **Roe MT**, Mulgund J, Newby LK, Smith SC Jr, Pollack CV Jr, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA, and the CRUSADE Investigators. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. *Arch Intern Med.* 2006;166:806-11. PMID: 16606819
303. Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC Jr, **Roe MT**. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol.* 2006;98:1172-76. PMID: 17056321.
304. Galla JM, Mahaffey KW, Sapp SK, Alexander JH. **Roe MT**, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. *Am Heart J.* 2006;151:16-24. PMID: 16368286.
305. Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV Jr., Kirk JD, Smith SC Jr., Gibler WB, Ohman EM, Blomkalns AL, Newby LK, Hochman JS, Peterson ED, **Roe MT**. Frequency and consequences of recording an electrocardiogram > 10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE initiative). *Am J Cardiol.* 2006;97:437-42. PMID: 16461033.
306. Newby LK, **Roe MT**, Chen AY, Ohman EM, Christenson RH, Pollack CV Jr, Hoekstra JW, Peacock WF, Harrington RA, Jesse RL, Gibler WB, Peterson ED. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. *J Am Coll Cardiol.* 2006;47:312-18. PMID: 16412853.

307. Brogan GX Jr., Peterson ED, Mulgund J, Bhatt DL, Ohman EM, Gibler WB, Pollack CV Jr., Farkouh ME, **Roe MT**. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. *Diabetes Care*. 2006;29:9-14. PMID: 16373888.
308. Yang X, Alexander KP, Chen AY, **Roe MT**, Brindis RG, Rao SV, Gibler WB, Ohman EM, Peterson ED for the CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: Results from CRUSADE. *J Am Coll Cardiol*. 2005;46:1490-95. PMID: 16226173.
309. Ryan JW, Peterson ED, Chen AY, **Roe MT**, Ohman EM, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV, Cohen DJ, for the CRUSADE Investigators. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes. Insights from the CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse outcomes with early implementation of the ACC/AHA guidelines) registry. *Circulation*. 2005;112:3049-57. PMID: 16275863.
310. Kandzari DE, **Roe MT**, Ohman EM, Milford-Beland S, Chen AY, Lytle BL, Cohen DJ, Smith SC Jr, Harrington RA, Gibler WB, Peterson ED. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. *Am J Cardiol*. 2005;96:750-55. PMID: 16169352.
311. Alexander KP, Chen AY, **Roe MT**, Newby KL, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. *JAMA*. 2005;294:3108-16. PMID: 16380591.
312. **Roe MT**, Peterson ED, Li Y, Pollack CV, Christenson RH, Peacock WF, Fesmire FM, Newby LK, Jesse RL, Hoekstra JW, Gibler WB, Ohman EM. Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. *Arch Intern Med*. 2005;165:1870-76. PMID: 16157831.
313. **Roe MT**, Parsons LS, Pollack CV, Canto JG, Barron HV, Every NR, Rogers WJ, Peterson ED. Quality of care by classification of myocardial infarction. *Arch Intern Med*. 2005;165:1630-36. PMID: 16043682.
314. Alexander KP, **Roe MT**, Chen AY, Lytle BL, Pollack CV Jr, Foody JM, Boden WE, Smith SC Jr, Gibler WB, Ohman EM, Peterson ED. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from CRUSADE. *J Am Coll Cardiol*. 2005;46:1479-87. PMID: 16226171.
315. **Roe MT**, Peterson ED, Pollack CV, Newby LK, Yun LI, Christenson RH, Peacock WF, Fesmire FM, Diercks D, Kirk D, Smith SC, Ohman EM, Gibler WB (For the CRUSADE Investigators) Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. *Ann Emerg Med*. 2005;45:355-62. PMID: 15795713.
316. Foody JM, **Roe MT**, Chen AY, Smith SC, Brindis RG, Peterson ED, Gibler WB, Ohman EM for the CRUSADE Investigators. Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). *Am J Cardiol*. 2005;95:483-85. PMID: 15695133.
317. Kirtane AJ, Weisbord A, Karmaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Ohman EM, **Roe MT**, Braunwald E, Gibson CM, (for the TIMI Study Group). Relation of impaired thrombolysis in myocardial infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. *Am J Cardiol*. 2005;95:224-27. PMID: 15642554.

318. **Roe MT**, Peterson ED. Improvements in Quality Improvement. *Am Heart J.* 2005;149:751-52. PMID: 15894952.
319. Atwater BD, **Roe MT**, Mahaffey KW. Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Segment Elevation Acute Coronary Syndromes (A review of guide to patient selection). *Drugs.* 2005;65:313-24. PMID: 15669877.
320. Rebeiz AG, Johanson P, Crater SW, **Roe MT**, Langer A, Giugliano RP, Lincoff AM, Newby LK, Harrington RA, Toprol EJ, Califf RM, Wagner GS, Krucoff MW. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (Data from four clinical trials). *Am J Cardiol.* 2005;95:611-14. PMID: 15721101.
321. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, **Roe MT**, Harrington RA, Ohman EM, Braunwald E, Gibson CM. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. *J Am Coll Cardiol.* 2005;45:321-23. PMID: 15653037.
322. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX, Boden WE, **Roe MT**, Ohman EM, Gibler WB, Newby LK, (For the CRUSADE Investigators). Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome-large scale observation from the CRUSADE quality improvement initiative. *J Am Coll Cardiol.* 2005;45:832-37. PMID: 15766815.
323. Kandzari DE, **Roe MT**, Chen AY, Lytle BL, Pollack CV, Jr., Harrington RA, Ohman EM, Gibler WB, and Peterson ED. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. *Am Heart J.* 2005;149:474-81. PMID: 15864236.
324. Pollack CV, Diercks DB, **Roe MT**, Peterson ED. 2004 American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction: Implications for emergency department practice. *Ann Emerg Med.* 2005;45:363-76. PMID: 15795714.
325. The ADVANCE MI Investigators (**Roe MT** - corresponding and lead author of writing group). Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated Addressing the value of facilitated angioplasty after combination therapy or eptifibatide monotherapy in acute myocardial Infarction (ADVANCE MI) Trial. *Am Heart J.* 2005;150:116-22. PMID: 16084157.
326. Hoekstra JW, **Roe MT**, Peterson ED, Menon V, Mulgund J, Li Y, Pollack CV Jr, Miller C, Palabrica T, Harrington RA, Ohman EM, Gibler WB. Early GP IIb/IIIa inhibitor use for non-ST-elevation acute coronary syndrome: patient selection and associated treatment patterns. *Acad Emerg Med.* 2005;12:431-38. PMID: 15863399.
327. Sonel AF, Good CF, Mulgund J, **Roe MT**, Gibler BG, Smith SC, Cohen MC, Pollack CV, Ohman EM, Peterson ED. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes. *Circulation.* 2005;111:1225-32. PMID: 15769762.
328. Gurjeva OS, **Roe MT**, Murphy SA, Moliterno DJ, Cannon CP; GUARANTEE Investigators. Unfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry). *Crit Pathw Cardiol.* 2005;4:81-87. PMID: 188340189.

329. Meine TJ, **Roe MT**, Chen AY, Patel MR, Washam JB, Ohman EM, Peacock WF, Pollack CV Jr, Gibler WB, Peterson ED. The association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE quality improvement initiative. *Am Heart J.* 2005;149:1043-49. PMID: 15976786.
330. Mahaffey KW, **Roe MT**, Kilaru R, French JK, Alexander JH, Berdan LG, van de Werf, Simoons ML, Weaver D, White HD, Lincoff MA, Kleiman NS, Toprol EJ, Harrington RA. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. *Am J Cardiol.* 2005; 95:1404-08. PMID: 15950560.
331. **Roe MT**, Peterson ED, Ohman EM, Smith SC, Gibler, WB. Overcoming the challenges facing quality improvement strategies for non-ST segment elevation acute coronary syndromes. *Am Family Physician.* 2004;70:2-4. PMID: 15571056.
332. Ohman EM, **Roe MT**, Smith SC, Brindis RG, Christenson RH, Harrington RA, Gibler WB, Peterson ED. Care of non-ST-segment elevation of patients: Insights from the CRUSADE national quality improvement initiative. *Am Heart J.* 2004;148:S34-S39. PMID: 15514632.
333. **Roe MT**. Success stories: How hospitals are improving care. *Am Heart J.* 2004;148:S52-S55. PMID: 15514636.
334. Yan AT, Jong P, Yan RT, Tan M, Fitchett D, Chow CM, **Roe MT**, Pieper KS, Langer A, Goodman SG (for the Canadian Acute Coronary Syndromes (ACS) Registry Investigators Toronto, Ontario, Canada, and Durham, NC). Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndromes. *Am Heart J.* 2004;148:1020-27. PMID: 15632888.
335. Waters RE, Singh KP, **Roe MT**, Lotfi M, Sketch MH, Jr, Mahaffey KW, Newby LK, Alexander JH, Harrington RA, Califf RM, Granger CB. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. *J Am Coll Cardiol.* 2004;43:2153-59. PMID: 15193673.
336. Gibson MC, Karha J, Murphy SA, Lemos JA, Morrow DA, Giugliano RP, **Roe MT**, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. *J Am Coll Cardiol.* 2004;43:1170-76. PMID: 15063425.
337. Yan AT, Tan M, Fitchett D, Chow CM, Fowles RA, McAvine TG, **Roe MT**, Peterson ED, Tu JV, Langer A. One-year outcome of patients after acute coronary syndromes (from the Canadian acute coronary syndromes registry). *Am J Cardiol.* 2004;94:25-29. PMID: 15219503.
338. Bhatt DL, **Roe MT**, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC, Pollack CV, Gibler WB, Ohman EM. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE quality improvement initiative. *JAMA.* 2004;17:2096-104. PMID: 15523070.
339. **Roe MT**, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CG, Ohman EM, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Toprol EJ. Creatinine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. *Eur Heart J.* 2004;25:313-21. PMID: 14984920.

340. **Roe, MT**, Green CL, Giugliano RP, Gibson CM, Baran K, Greenberg M, Palmeri ST, Crater, S, Trollinger K, Hannan K, Harrington RA, Krucoff MW. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. *J Am Coll Cardiol.* 2004;43:549-56. PMID: 14975462.
341. Giugliano RP, Sabatine MS, Gibson CM, **Roe MT**, Harrington RA, Murphy SA, Morrow DA, Antman EM, Braunwald E. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate pericardial and myocardial reperfusion. *Am J Cardiol.* 2004;93:1362-67. PMID: 15165915.
342. Rebeiz AG, **Roe MT**, Alexander JH, Mahaffey KW, Granger CB, Peterson, ED, Califf RM, Harrington RA. Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. *Am J Med.* 2004;116:119-29. PMID: 14715326.
343. Gibson CM, Karha J, Giugliano RP, **Roe MT**, Murphy SA, Harrington RA, Green CL, Schweiger MJ, Miklin JS, Baran KW, Palmeri S, Braunwald E, Krucoff MW. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. *Am Heart J.* 2004;147:847-52. PMID: 15131541.
344. Waters RE, Mahaffey KW, Granger GB, **Roe, MT**. Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: Integrating pharmacological and mechanical reperfusion strategies. *Am Heart J.* 2003;146:958-68. PMID: 14660986.
345. Gibson MD, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, **Roe MT**, Harrington RA, Ohman EM, Antman M. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. *J Thromb and Thrombolysis.* 2003;15:189-96. PMID: 14739628.
346. Pollack CV, **Roe MT**, Peterson ED. 2002 Update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: Implications for emergency department practice. *Ann Emerg Med.* 2003;41:355-69. PMID: 12605203.
347. Fesmire FM, Peterson ED, **Roe MT**, Wojcik JF. Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: A local quality improvement initiative. *Am J Emer Med.* 2003;21:302-08. PMID: 12898487.
348. Giugliano RP, **Roe MT**, Harrington, RA, Gibson CM, Zeymer U, van de Werf, Baran KW, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction. *J Am Coll Cardiol.* 2003;41:1251-60. PMID: 12706917.
349. Peterson ED, Pollack CV, **Roe MT**, Parsons LS, Littrell KA, Canto JG, Barron HV. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction. *J Am Coll Cardiol.* 2003;42:45-53. PMID: 12849658.
350. **Roe MT**, Ohman ME, Pollack CV, Peterson ED, Brindis RG, Harrington, RA, Christenson RH, Smith SC, Califf RM, Gibler BW. Changing the model of care for patients with acute coronary syndromes. *Am Heart J.* 2003;146:605-23. PMID: 14564312.

351. **Roe MT**, Christenson RH, Ohman M, Bahr R, Fesmire FM, Storrow A, Mollod M, Peacock F, Rosenblatt JA, Yang H, Fraulo E, Hoekstra J, Gibler WB. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. *Am Heart J.* 2003;146:993-98. PMID: 14660990.
352. Gurbel PA, Galbut B, Bliden KP, Bahr RD, **Roe MT**, Serebruany VL, Gibler WB, Christenson RH, Ohman EM; EARLY Platelet Substudy. Effect of eptifibatide for acute coronary syndromes: Rapid versus late administration—therapeutic yield on platelets. *J Thromb Thrombolysis.* 2002;14:213-19. PMID: 12913401.
353. **Roe MT**, Staman KL, Pollack C, Teaff R, French PA, Peterson ED. A practical guide to understanding the 2002 ACC/AHA guidelines for the management of patients with non-ST segment elevation acute coronary syndromes. *Crit Pathw Cardiol.* 2002;1:129-49. PMID: 18340297.
354. Hoekstra JW, Pollack CV, **Roe MT**, Peterson ED, Brindis R, Harrington RA, Christenson RH, Smith SC, Ohman EM, Gibler WB: Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department - The CRUSADE initiative. *Acad Emer Med.* 2002;9:1146-55. PMID: 12414463.
355. Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup DS, Dyke C, **Roe MT**, Berdan L, Lauer MS, Manttari M, White HD, Califf RM, Topol EJ. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from platelet IIb/IIa antagonist for the reduction of acute coronary syndrome events in a global organization network B (PARAGON B) *Am Heart J.* 2002;144:995-1002. PMID: 12486423.
356. Bahr RD, Gurbel PA, Malinin AL, Wentz C, Christenson RH, **Roe MT**, Gibler WB, Kitt MM, Ohman EM, Serebruany VL. Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. *Am J Cardiol.* 2002;90:310-12. PMID: 12127619.
357. Mahaffey KW, **Roe MT**, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. *Am Heart J.* 2002;143:242-48. PMID: 11835026.
358. Kandazari DE, **Roe MT**. Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction. *J Inv Cardiol.* 2002;14:565-74. PMID: 12205361.
359. **Roe MT**, Ohman EM, Maas ACP, Christenson RH, Mahaffey KW, Granger CB, Harrington RA, Califf RM, Krucoff MW. Shifting the open artery hypothesis downstream: the quest for optimal reperfusion. *J Am Coll Cardiol.* 2001;37:9-18. PMID: 11153779.
360. Peterson JG, Topol EJ, **Roe MT**, Sapp SK, Lincoff AM, Deckers JW, Blackstone EH, Harrington RA, Califf RM, Lauer MS. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. *Am J Cardiol.* 2001;87:532-36. PMID: 11230834.
361. Aronow HD, Topol EJ, **Roe MT**, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. *Lancet.* 2001;357:1063-68. PMID: 11297956.

362. **Roe MT**, Cura F, Joski PS, Garcia E, Guetta V, Kereiakes DJ, Zijlstra F, Brodie BR, Grines CL, Ellis SG. Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. *Am J Cardiol.* 2001;88:170-73. PubMed PMID: 11448417.
363. Mukherjee D, Comella K, Bhatt DL, **Roe MT**, Patel V, Ellis SG. Clinical outcome of a cohort of patients eligible for transmyocardial revascularization. *Am Heart J.* 2001;142:72-74. PMID: 11431659.
364. Christenson RH, Duh SH, **Roe MT**, Ohman EM. Determination of the falloff constant (k_f) from modeling biochemical marker release. A new variable for discriminating therapies. *Cardiovascular Toxicology.* 2001;1:171-6. PMID: 12213991.
365. **Roe MT**, Granger CB, Puma JA, Hellkamp AS, Hochman JS, Ohman EM, White HD, van de Werf F, Armstrong PW, Ellis SG, Califf RM, Topol EJ. Comparison of benefits and complications of hirudin vs. heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. *Am J Cardiol.* 2001;88:1403-06. PMID: 11741559.
366. **Roe MT**, Abramson MA, Li J, Heinle SK, Kisslo J, Corey GR, Sexton DJ. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the Duke criteria. *Am Heart J.* 2000;139:445-51. PMID: 10827373.
367. **Roe MT**, Harrington RA, Prosper DM, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Pieper KS, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Clinical and therapeutic profile of patients with acute coronary syndromes who do not have significant coronary artery disease. *Circulation.* 2000;102:1101-06. PMID: 10973837.
368. Marso SP, Bhatt DL, **Roe MT**, Houghtaling PL, Labinaz M, Kleiman NS, Dyke C, Simoons ML, Califf RM, Harrington RA, Topol EJ. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndromes requiring in-hospital coronary artery bypass grafting. *Circulation.* 2000;102:2952-58. PMID: 11113045.
369. Mukherjee D, Bhatt DL, **Roe MT**, Patel VS, Ellis SG. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. *Am J Cardiol.* 1999;84:598-600. PMID: 11431659
370. **Roe MT**, Moliterno DJ. Treatment of non-ST-segment elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa Inhibitors: An emergency department perspective. *J Emer Med.* 1999;17:581-88. PMID: 10338260.
371. **Roe MT**, Moliterno DJ. Emerging treatment of acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors. *J Thrombosis and Thrombolysis.* 1999;7:247-57. PMID: 10373718.
372. **Roe MT**, Hulette CM, Einstein G, Crain BC. Reactive microglia are not exclusively associated with plaque-rich regions of the dentate gyrus in Alzheimer's Disease. *J Neuropath and Exp Neurology.* 1996;55:366-71. PMID: 8786395.
373. Weinstein JW, **Roe MT**, Towns MT, Sanders L, Thorpe J, Corey GR, Sexton DJ. Resistant enterococci: A prospective study of prevalence, incidence, and factors associated with colonization in a university hospital. *Infect Control and Hosp Epidemiol.* 1996;17:36-41. PMID: 8789685.

374. Gopal AK, **Roe MT**, Calcified cardiac lesion. *Chest*. 1996;110:1097-98. PMID: 8874274. **Roe MT**, Anderson PC, Dunn AD, Dunn JT. The hormonogenic sites of turtle thyroglobulin and their homology with those of mammals. *Endocrinology*. 1989;124:1327-32. PMID: 2917515.

Chapters in Books

1. Kang HJ, **Roe MT**. Secondary Prevention of ACS: The Role of Novel Anticoagulants. In: Pharmacological treatment of acute coronary syndromes. 2013. Editors: Avanzas P, Clemmensen P. Springer-Verlag, London. Pages 123-138
2. Brito F, Lopes RD, **Roe MT**. Coronary artery disease. In: Atherothrombosis in clinical practice. 2013. Editors: Bhatt DL, Baliga RR. Oxford University Press, New York, NY. Pages 19-37.
3. Vavalle JP, Alexander HJ, **Roe MT**. Acute coronary syndromes manifestations and management. In: Hemostasis and thrombosis – basic principles and clinical practice. Sixth edition. 2012. Editors: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC. Lippincott, Williams, and Wilkins, Philadelphia, PA. Pages 1064-1086.
4. Atwater BD, Wang A, **Roe MT**. Wilderness cardiology. In: Wilderness medicine. 2007. Editor: Auerbach PS. Mosby Elsevier, Philadelphia, PA. Pages 644-654.
5. Singh, K, **Roe MT**, Harrington RA. Design and overview of contemporary studies of pharmacoinvasive therapy. In: Pharmacoinvasive therapy in acute myocardial infarction. 2005. Editors: Dauerman HL, Sobel BE. Marcel Dekker Publishers, New York, New York, Pages 183-208.
6. Trichon BH, **Roe MT**. Diabetes Mellitus and ischemic heart disease. In: Diabetes and cardiovascular disease. 2004. Editors: Marso S, Stern D. Lippincott Williams & Wilkins, Philadelphia, PA Pages 355 – 377.
7. Trichon BH, **Roe MT**. Ischemic coronary syndromes. In: The handbook of diabetes mellitus and cardiovascular disease. 2003. Editor: Marso SM. Remedica. Lincolnshire, IL. Pages 131-156.
8. **Roe MT**. Intra-aortic balloon counterpulsation. In: The manual of cardiovascular medicine. 2000. Editors: Marso SM, Griffin BG, Topol EJ. Lippincott, Williams, and Wilkins. Philadelphia, PA. Pages 687-99.
9. **Roe MT**. Unstable angina and non-ST-segment elevation myocardial infarction. 2000. In: The manual of cardiovascular medicine. Editors: Marso SM, Griffin BG, Topol EJ. Lippincott, Williams, and Wilkins. Philadelphia, PA. Pages 25-38.

Clinical Research Experience and Positions

- 1) Eptifibatide for Acute coronary syndromes: Rapid versus Late Administration for therapeutic Yield (EARLY) Trial (Early vs. Delayed Administration of Glycoprotein IIb/IIIa Inhibitors for Unstable Angina/Non-ST-Elevation Myocardial Infarction)
 - Trial Co-Principal Investigator: 1999 – 2001
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 1999-2001

- 2) INTEGRITIlin and Tenecteplase in acute myocardial Infarction (INTEGRITI) Trial (Combination Reperfusion Therapy for Acute ST-Elevation Myocardial Infarction)
 - Trial Co-Principal Investigator: 1999 – 2001
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 1999-2001
- 3) Comparision of New Stents for Equivalency of Reduction in Vascular Events (CONSERVE) Trial
 - Member of Data Safety Monitoring Board: 2000 – 2001
- 4) Evaluating ENOX Clotting Times (ELECT) Trial
 - Chairman of Data Safety Monitoring Board: 2001-2002
- 5) Can Rapid Risk Stratification of Unstable Angina Patients Suppresss Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) National Quality Improvement Initiative (Nationwide Registry for Unstable Angina/Non-ST-Elevation Myocardial Infarction in the United States)
 - Study Co-Principal Investigator: 2000 – 2006
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2000-2006
- 6) Addressing the Value of Facilitated Angioplasty Compared with Eptifibatide Monotherapy for Acute Myocardial Infarction (ADVANCE MI) Trial (Combination Reperfusion Therapy for Acute ST-Elevation Myocardial Infarction)
 - Trial Co-Principal Investigator: 2001-2003
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2001-2003
- 7) Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Trial (Novel Agent to Mitigate Reperfusion Injury for Acute ST-Elevation Myocardial Infarction)
 - Trial Principal Investigator: 2003 – 2007
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2003-2007
- 8) American College of Cardiology - Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-GWTG (Nationwide Registry for Acute Myocardial Infarction in the United States)
 - Steering Committee – Ex Officio Member: 2006-2010
 - Research and Publications Committee – Chairman: 2007-2010:
 - Duke Clinical Research Institute Data Analytic Center – Principal Investigator: 2007-present
- 9) Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) Trial (Prasugrel vs. Clopidogrel for Medically Managed Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction)
 - Trial Principal Investigator: 2006 - 2012
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2006-2012
- 10) American College of Cardiology – National Cardiovascular Data Registry (NCDR) Cath/PCI Registry (Nationwide Registry for Percutaneous Coronary Intervention in the United States)
 - Research and Publications Committee – Ex Officio Member: 2009-present
 - Duke Clinical Research Institute Data Analytic Center – Principal Investigator: 2006-present
- 11) Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Elevation Acute Coronary Syndromes (EARLY ACS) Trial
 - Chairman of Clinical Events Adjudication Committee: 2006-2008
- 12) Early Rapid Reversal of Platelet Thrombosis with Intravenous PRT060128 Before PCI to Optimize Reperfusion in Acute MI (ERASE MI) Trial (Intravenous P2Y12 Inhibitor Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction)
 - Trial Co-Principal Investigator: 2007 – 2009

- Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2007-2009
- 13) Enhancing Chronic Post MI Treatment by Clarifying the Optimal Platelet Inhibition in Secondary Prevention (ECLIPSE) Trial (Elinogrel vs. Clopidogrel for Long-Term Treatment After Acute Myocardial Infarction)
 - Trial Principal Investigator: 2010 - 2011
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2010-2011
 - 14) American Heart Association Mission Lifeline Program (Nationwide Quality Improvement Initiative for ST-Elevation Myocardial Infarction in the United States)
 - Duke Clinical Research Institute Data Analytic Center –Principal Investigator: 2010-present
 - 15) Dalcetrapib for the Treatment of Patients with Stable Coronary Heart Disease [CHD], CHD Risk Equivalents, or at Elevated Risk for Cardiovascular Disease (dal-OUTCOMES-2) Trial (CETP Inhibitor for the Treatment of Chronic Cardiovascular Disease)
 - Member of Executive Committee: 2011-2013
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2011-2013
 - 16) PCS-K9 Monoclonal Antibody SAR236553/REGN727 to Reduce the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome – the ODYSSEY Outcomes Trial (Novel Lipid Lowering Agent for Patients with Recent Acute Coronary Syndromes)
 - Member of Steering Committee, United States National Lead Investigator: 2012-present
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2012-present
 - 17) The Familial Hypercholesterolemia Foundation CASCADE-FH Registry (Nationwide Registry for Familial Hyperlipidemia in the United States)
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2013-present
 - 18) Tailored Antiplatelet Therapy Following Percutaneous Coronary Intervention (TAILOR-PCI) Trial
 - Member of Data Safety and Monitoring Board: 2013-present
 - 19) Clinical Trials Transformation Initiative (CTTI) - <http://www.ctti-clinicaltrials.org>
 - Team Leader - Investigator Turnover and Clinical Trial Site Performance and Quality Project: 2013-present
 - 20) EVOLVE AF-PCI Trial (Edoxaban vs. Vitamin K Antagonists for Atrial Fibrillation Patients Undergoing PCI)
 - Member of Executive Committee: 2014-2015
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2014-2015
 - 21) GEMINI-1 ACS Trial (Rivaroxaban vs. Low-Dose Aspirin with a P2Y12 Inhibitor After Acute Coronary Syndromes)
 - Member of Executive Committee: 2014-Present
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2014-present
 - 22) ADAPTABLE Trial (Low vs. High-Dose Aspirin for Chronic Cardiovascular Disease) – www.theaspirinstudy.org
 - Trial Co-Principal Investigator: 2015-Present
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2015-present
 - 23) PRONOUNCE Trial (A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix [GnRH Receptor Antagonist] or Leuprolide [GnRH Receptor Agonist])
 - Steering Committee Co-Chairman: 2015-Present
 - Principal Investigator for the Duke Clinical Research Institute Academic Coordinating Center: 2015-present

Administrative Positions

1) Co-Director of Duke Cardiovascular Medicine Outpatient Clinics

- Oversight and supervision of reconfiguration of outpatient clinical services
- July, 2005 – June, 2007

2) Duke Clinical Research Institute - Associate Research Fellowship Director

- Supervision of cardiovascular research fellows during the 2 years of dedicated research training
- September, 2005 – June, 2010

3) AHA Pharmaceutical Roundtable Outcomes Research Center – Fellowship Director

- Director for Fellowship Program at the Duke Clinical Research Institute Outcomes Research Center
- September, 2008 – June, 2013

4) Duke Clinical Research Institute - Research Fellowship Director

- Supervisor of the Duke Clinical Research Institute Clinical Research Fellowship
- June, 2010 – Present

5) Duke Clinical Research Institute - Faculty Director, Global Outcomes Commercial Megatrials

- Faculty leader of the operational group that conducts large, global, randomized cardiovascular outcomes trials at the Duke Clinical Research Institute Academic Coordinating Center
- May, 2013 – Present

6) Duke University Medical Center, Division of Cardiology – Associate Fellowship Director

- Supervision of clinical research activities for cardiology fellows during dedicated research years
- May, 2013 – Present

7) Duke Clinical Research Institute - Faculty Director, DCRI Think Tank Series

- Strategic planning, topic development, and faculty support for quarterly Think Tank meetings involving academic, government, and industry leaders coordinated by the DCRI
- April, 2015 – Present

8) Duke Clinical Research Institute – Member of Core 2.0 Operational Improvement Initiative

- Faculty representative to the core operational team that prioritizes resource allocation and key objectives for operational improvements across the Duke Clinical Research Institute
- November, 2016 - Present

9) Duke Clinical Research Institute – Faculty Council

- Member of committee tasked with developing strategies and solutions for key issues related to faculty performance and satisfaction at the Duke Clinical Research Institute
- January, 2017 - Present

Awards and Achievements

1) Robert M. Califf Mentorship Award – June, 2008

- Awarded annually by research fellows at the Duke Clinical Research Institute

Past Mentored Trainees

1. Mark Y. Chan, MBBS, MHS
Training Years in DCRI Clinical Research Fellowship Program: 2006-2008
Current Position: Faculty, National University Heart Center, Singapore
Number of First Authored Publications to Date: 27
2. Sergio Leonardi, MD, MHS
Training Years in DCRI Clinical Research Fellowship Program: 2009-2012
Current Position: Faculty, Cardiology Division, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Number of First Authored Publications to Date: 11
3. Chee Tang Chin, MB ChB
Training Years in DCRI Clinical Research Fellowship Program: 2009-2010
Current Position: Faculty, National Heart Center, Singapore
Number of First Authored Publications to Date: 11
4. Connie Hess, MD, MHS
Training Years in DCRI Clinical Research Fellowship Program: 2011-2013
Current Position: Faculty, Cardiology Division, University of Colorado, Denver, CO
Number of First Author Publications to Date: 23
5. Akshay Bagai, MD, MHS
Training Years in DCRI Clinical Research Fellowship Program: 2011-2013
Current Position: Faculty, Cardiology Division, University of Toronto, Canada
Number of First Author Publications to Date: 23
6. Hyun-Jae Kang, MD
Training Years in DCRI Clinical Research Fellowship Program: 2012-2014
Current Position: Faculty, Cardiology Division, Seoul National University, Seoul, South Korea
Number of First Author Publications to Date: 23
7. Emil Hagstrom, MD
Training Years in DCRI Clinical Research Fellowship Program: 2013-2014
Current Position: Faculty, Cardiology Division, Uppsala University, Uppsala, Sweden
Number of First Author Publications to Date: 10
8. Joakim Alfredsson, MD, PhD
Training Years in DCRI Clinical Research Fellowship Program: 2014 – 2015
Current Position: Faculty, Cardiology Division, Linköping University Hospital, Sweden
Number of First Author Publications to Date: 6
9. Larry Jackson, MD
Training Years in DCRI Clinical Research Fellowship Program: 2014 – 2015
Current Position: Faculty, Cardiology Division, Duke Medical Center
Number of First Authored Publications to Date: 6
10. Christopher Fordyce, MD
Training Years in DCRI Clinical Research Fellowship Program: 2014-2016
Current Position: Faculty, Division of Cardiology, University of British Columbia
Number of First Authored Publications to Date: 15

Duke University Medical Center Committees

2002	Cardiology Quality Improvement Planning Committee Rapid Transfer for Primary Angioplasty Committee
2003	Cardiology Quality Improvement Planning Committee Rapid Transfer for Primary Angioplasty Committee
2004	Cardiology Quality Improvement Planning Committee Rapid Transfer for Primary Angioplasty Committee
2005	Cardiology Quality Improvement Planning Committee Rapid Transfer for Primary Angioplasty Committee Cardiology Outpatient Clinic Leadership Committee Cardiology Inpatient Clinical Redesign Committee
2006	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Cardiovascular Medicine Outpatient Clinic Leadership Committee Cardiovascular Medicine Inpatient Clinical Redesign Committee Cardiovascular Medicine Performance Improvement Board Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2007	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Cardiovascular Medicine Outpatient Clinic Leadership Committee Cardiovascular Medicine Performance Improvement Board Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2008	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Cardiovascular Medicine Performance Improvement Board Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2009	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Cardiovascular Medicine Performance Improvement Board Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2010	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Heart Center Cardiology Outcomes Committee Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2011	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Heart Center Cardiology Outcomes Committee Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee

2012	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Heart Center Cardiology Outcomes Committee Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2013	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Heart Center Cardiology Outcomes Committee Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2014	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Heart Center Cardiology Outcomes Committee Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2015	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Heart Center Cardiology Outcomes Committee Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee
2016	Time to Reperfusion for ST-Elevation Myocardial Infarction Committee Heart Center Cardiology Outcomes Committee Cardiovascular Medicine Fellowship Selection Committee Cardiovascular Medicine Fellowship Mentorship Committee

National/International Invited Lectures (for the past five years, in reverse chronological order)

- American Heart Association Scientific Sessions (New Orleans, LA, November 12-16, 2016). *(1) Early Lessons from PCORnet Trials: ADAPTABLE; (2) Electronic Facilitation of Clinical Trials: e-Identification, e-Consent, e-Randomization, e-Follow-up.*
- Cardiac Safety Research Consortium Think Tank Meeting: Cardiac Safety Assessment – Opportunities Beyond the Randomized Clinical Trial (Rockville, MD, October 19, 2016). *Pragmatic Trial Designs – capturing endpoints and integrating data from non-linked sources.*
- Endovascular and Coronary Revascularization in Seoul Annual Meeting (Seoul, South Korea, October 6-7, 2016). *(1) Balancing the risks of ischemia vs bleeding with prolonged dual anti platelet therapy after ACS and PCI; (2) Choice of antiplatelet agents according to the clinical situations.*
- Society of Clinical Trials Annual Meeting (Montreal, Quebec, May 17, 2016): *Pragmatic Clinical Trials - Attributes, Recent Experiences, and Overcoming Barriers to Implementation.*
- Food and Drug Administration Public Hearing: Confidentiality of Interim Results in Cardiovascular Outcomes Safety Trials (Silver Spring, MD, August 11, 2014): *Pros and Cons of Releasing Interim Results in Cardiovascular Outcomes Safety Trials – Representing the Consensus Position of the American Heart Association*
- American College of Cardiology Scientific Sessions (Washington, DC, March 30, 2014). *Turning ACTION-GWTG Registry Data Into Actionable Improvements in the Care of the Stable Ischemic Heart Disease Patient.*
- Familial Hypercholesterolemia Summit (Annapolis, MD, September 19, 2013). *Success of Registries in Cardiovascular Disease.*
- China Heart Congress (Beijing, China, August 9, 2013). *What Can We Learn from the NCDR ACTION Registry-GWTG and Cath-PCI Registries?*
- Cardiometabolic Health Congress (Boston, MA, October 13, 2012). *ACS Patients with Diabetes Should Not Receive Personalized Anti-Platelet Therapies.*

- European Society of Cardiology Scientific Sessions – Late Breaking Clinical Trial Session (Munich, Germany, August 26, 2012). *Final Results from the TRILOGY-ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) Trial.*
- American College of Cardiology Scientific Sessions (Chicago, IL, March 25, 2012). *Safety, Cost, and Quality Are the New Drivers of NSTEMI ACS Care.*